

Rec'd PCT/PTO 13 JAN 2005

REC'D 17 OCT 2003

WIPO

PCT

PL 1078384

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 10, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/426,601

FILING DATE: November 15, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/21706



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

L. Edeleⁿ

L. EDELEN
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

11/15/02
USPTO

11-18-02 601-26601 A/P/PTO

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)		
Given Name (first and middle [if any]) Kevin S.	Family Name or Surname Brandt	Residence (City and either State or Foreign Country) 7114 Woodrow Dr. Fort Collins, CO 80525
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (280 characters max) "TICK OCTOPAMINE RECEPTOR NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF"		
Direct all correspondence to:		CORRESPONDENCE ADDRESS
<input checked="" type="checkbox"/> Customer Number	26949	Place Customer Number here 26949
OR Type Customer Number here		
<input type="checkbox"/> Firm or Individual Name	PATENT TRADEMARK OFFICE	
Address		
Address	State	ZIP
City		
Country	Telephone	Fax
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification	Number of Pages 50	<input type="checkbox"/> CD(s), Number
<input type="checkbox"/> Drawing(s)	Number of Sheets	<input checked="" type="checkbox"/> Other (specify) 12 pages Sequence Listing
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number 081930	\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input type="checkbox"/> No.		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____		

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Timothy L. McCutcheon, Esq.

970-493-7272, ext. 4182

TELEPHONE

Date

11/15/02

REGISTRATION NO.
(if appropriate)

41,184

Docket Number:

P-FC-10

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C.

P18SMALL/REV05

610426601 2.1.1502

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No. P-FC-10
Applicant(s): Kevin S. Brandt			
Serial No.	Filing Date November 15, 2002	Examiner	Group Art Unit
Invention: "TICK OCTOPAMINE RECEPTOR NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF"			
<p>I hereby certify that the following correspondence:</p> <p>Certificate of Mailing by "Express Mail"; Original and one copy of Provisional Application for Patent Cover Sheet; 50 pages of specification, claims and abstract; 12 pages of Sequence Listing; and acknowledgment postcard</p> <p><i>(Identify type of correspondence)</i></p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on</p>			
<p>November 15, 2002 <i>(Date)</i></p> <p>Susan A. Gordon <i>(Typed or Printed Name of Person Mailing Correspondence)</i></p> <p><i>Susan A. Gordon</i> <i>(Signature of Person Mailing Correspondence)</i></p> <p>EL344802074US <i>("Express Mail" Mailing Label Number)</i></p>			

**TICK OCTOPAMINE RECEPTOR NUCLEIC ACID MOLECULES,
PROTEINS AND USES THEREOF**

FIELD OF THE INVENTION

The present invention relates to tick octopamine receptor nucleic acid molecules,
5 proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and
inhibitors of such proteins. The present invention also includes methods to obtain such
proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present
invention also includes therapeutic compositions comprising such inhibitors, as well as uses
thereof.

10

BACKGROUND OF THE INVENTION

Tick infestation of animals is a health and economic concern for pet owners. Ticks
are known to carry a variety of infectious agents including, but not limited to bacteria,
viruses, protozoan parasites, and rickettsia. As such, ticks are a problem not only when they
are on an animal but also when they are in the general environment of the animal.

15

The medical importance of tick infestation has prompted the development of reagents
capable of controlling tick infestation. Commonly encountered methods to control tick
infestation are generally focused on use of insecticides, which are often unsuccessful for one
or more of the following reasons: (1) failure of owner compliance (frequent administration is
required); (2) behavioral or physiological intolerance of the pet to the pesticide product or
20 means of administration; and (3) the emergence of tick populations resistant to the prescribed
dose of pesticide.

Octopamine receptor is a member of the biogenic amine receptor family, which also
includes receptors for dopamine, serotonin, and tyramine. Octopamine is a major
neuromodulator in insects with neurotransmitter and neurohormone functions and is a known
25 activator of adenylate cyclase, resulting in stimulation of cyclic AMP production.

Prior investigations have described certain insect biogenic amine receptors in
Drosophila melanogaster, including for example, Arakawa et al. 1990, *Neuron*, 2:343-354,

Venter et al., U.S. Patent Number 5,474,898, Saudou et al., 1990, *EMBO Journal*, 9(11):3611-3617, and Han et al., 1998, *J. Neuroscience*. 18(10):3650-3658. Unfortunately, members of the biogenic amine receptor family have proven difficult to clone due to the rarity of the sequence as cDNA and often have highly related sequences and activities, which 5 has resulted in confusion in the art with respect to the true identity of reported sequences.

Insect octopamine receptor is a known target of various insecticides, including formamidine compounds such as demethylchlormeform (DCDM). However, no formamidine compound to date has been shown to be safe and efficacious for use for treating tick infestations on a host animal. Octopamine receptor is not present in vertebrates and 10 within insects susceptibility to insecticides targeting the octopamine receptor have been shown to vary by species. Therefore, in order to create compounds and treatments which are efficacious against ticks while minimizing toxicity to the host animal or to non-target insects, it would be a distinct advantage to have the sequence of the tick octopamine receptor. Accordingly, isolation and sequencing of tick octopamine receptor genes may be critical for 15 use in identifying specific agents for treating animals for tick infestation.

SUMMARY OF THE INVENTION

The present invention provides tick octopamine receptor proteins; nucleic acid molecules encoding tick octopamine receptor proteins; antibodies raised against such proteins (i.e., anti-tick octopamine receptor antibodies); mimetopes of such proteins or 20 antibodies; and compounds that inhibit tick octopamine receptor activity (i.e. inhibitory compounds or inhibitors).

The present invention also includes methods to obtain such proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds. The present invention also includes the use of proteins and antibodies to identify such inhibitory compounds as well as 25 assay kits to identify such inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds of the present invention including therapeutic compounds derived

from a protein of the present invention that inhibit the activity of tick octopamine receptor proteins.

One embodiment of the present invention is an isolated tick octopamine receptor nucleic acid molecule of at least 50 nucleotides that hybridizes with a nucleic acid sequence having SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12, under conditions that allow less than or equal to 5% base pair mismatch, wherein such nucleic acid molecule encodes a protein that binds octopamine, or a nucleic acid molecule having a sequence fully complementary to such a nucleic acid molecule. Another embodiment of the present invention is an isolated tick octopamine receptor nucleic acid molecule having a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12 or a fragment thereof having at least 50 nucleotides that encodes a protein that binds octopamine. Another embodiment of the present invention is an isolated tick octopamine receptor nucleic acid molecule that encodes a protein that is at least 95% identical to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, or a fragment thereof having at least 50 nucleotides that encodes a protein that binds octopamine, or a nucleic acid sequence fully complementary to such a nucleic acid sequence.

The present invention also relates to recombinant molecules, recombinant viruses and recombinant cells that include a nucleic acid molecule of the present invention. Also included are methods to produce such nucleic acid molecules, recombinant molecules, recombinant viruses and recombinant cells. Also included are methods to produce a protein of the present invention.

Another embodiment of the present invention includes an isolated tick octopamine receptor protein that is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, wherein such protein binds to octopamine.

Another embodiment of the present invention includes an isolated tick octopamine receptor protein encoded by a nucleic acid molecule that hybridizes with a nucleic acid sequence having SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12, under conditions that allow less than or equal to 5% base pair mismatch.

- 5 Another embodiment of the present invention includes a method to detect an inhibitor of tick octopamine receptor activity, said method comprising (a) contacting an isolated tick octopamine receptor protein of the present invention, with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has tick octopamine receptor protein activity, and (b) determining if said putative inhibitory compound inhibits
10 tick octopamine receptor protein activity.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for tick octopamine receptor nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. As used herein, tick octopamine receptor nucleic acid molecules 15 and proteins encoded by such nucleic acid molecules are also referred to as octopamine receptor nucleic acid molecules and proteins of the present invention, respectively. Tick octopamine receptor nucleic acid molecules and proteins of the present invention can be isolated from a tick or prepared recombinantly or synthetically. Tick octopamine receptor nucleic acid molecules of the present invention can be RNA or DNA, or modified forms thereof, and can be double-stranded or single-stranded; examples of nucleic acid molecules include, but are not limited to, complementary DNA (cDNA) molecules, genomic DNA 20 molecules, synthetic DNA molecules, DNA molecules which are specific tags for messenger RNA, and corresponding mRNA molecules. As such, a tick nucleic acid molecule of the present invention is not intended to refer to an entire chromosome within which such a nucleic acid molecule is contained, however, a tick octopamine receptor nucleic acid 25 molecule of the present invention may include all regions such as regulatory regions that control production of tick octopamine receptor proteins encoded by such a nucleic acid

molecule (such as, but not limited to, transcription, translation or post-translation control regions) as well as the coding region itself, and any introns or non-translated coding regions. As used herein, the phrase "tick octopamine receptor protein" refers to a protein encoded by a tick octopamine receptor nucleic acid molecule.

5 Tick octopamine receptor nucleic acid molecules of known length isolated from a tick, such as *Rhipicephalus sanguineus* are denoted "nRsOCR_#", for example nRsOCR₁₄₄₃, wherein "#" refers to the number of nucleotides in that molecule, and tick octopamine receptor proteins of known length are denoted "PRsOCR_#" (for example PRsOCR₄₈₀) wherein "#" refers to the number of amino acid residues in that molecule.

10 The present invention also provides for tick octopamine receptor DNA molecules that are specific tags for messenger RNA molecules. Such DNA molecules can correspond to an entire or partial sequence of a messenger RNA, and therefore, a DNA molecule corresponding to such a messenger RNA molecule (i.e. a cDNA molecule), can encode a full-length or partial-length protein. A nucleic acid molecule encoding a partial-length protein can be used directly as a probe or indirectly to generate primers to identify and/or isolate a cDNA nucleic acid molecule encoding a corresponding, or structurally related, full-length protein. A cDNA encoding a partial-length octopamine receptor protein can also be used in a similar manner to identify a genomic nucleic acid molecule, such as a nucleic acid molecule that contains the complete gene including regulatory regions, exons and introns.

15 Methods for using cDNA molecules and sequences encoding partial-length tick octopamine receptor proteins to isolate nucleic acid molecules encoding full-length tick octopamine receptor proteins and corresponding cDNA molecules are described in the examples herein below.

20 The proteins and nucleic acid molecules of the present invention can be obtained from their natural source, or can be produced using, for example, recombinant nucleic acid technology or chemical synthesis. Also included in the present invention is the use of these

proteins and nucleic acid molecules as well as antibodies and inhibitory compounds thereto as therapeutic compositions, as well as in other applications, such as those disclosed below.

One embodiment of the present invention is an isolated protein that includes a tick octopamine receptor protein. It is to be noted that the term "a" or "an" entity refers to one or 5 more of that entity; for example, a protein, a nucleic acid molecule, an antibody and a therapeutic composition refers to "one or more" or "at least one" protein, nucleic acid molecule, antibody and therapeutic composition respectively. As such, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably. 10 According to the present invention, an isolated, or biologically pure, protein, is a protein that has been removed from its natural milieu. As such, "isolated" and "biologically pure" do not necessarily reflect the extent to which the protein has been purified. An isolated protein of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology, or can be produced by chemical synthesis.

15 As used herein, isolated tick octopamine receptor proteins of the present invention can be full-length proteins or any homologue of such proteins. An isolated protein of the present invention, including a homologue, can be identified in a straight-forward manner by the protein's ability to elicit an immune response against a tick octopamine receptor protein or by the protein's ability to exhibit tick octopamine receptor activity, e.g. the ability to bind 20 to octopamine. Examples of tick octopamine receptor homologue proteins include tick octopamine receptor proteins in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycerophosphatidyl inositol) such that the 25 homologue includes at least one epitope capable of eliciting an immune response against a tick octopamine receptor protein, and/or of binding to an antibody directed against a tick octopamine receptor protein. That is, when the homologue is administered to an animal as an

immunogen, using techniques known to those skilled in the art, the animal will produce an immune response against at least one epitope of a natural tick octopamine receptor protein. The ability of a protein to effect an immune response can be measured using techniques known to those skilled in the art. As used herein, the term "epitope" refers to the smallest portion of a protein or other antigen capable of selectively binding to the antigen binding site of an antibody or a T cell receptor. It is well accepted by those skilled in the art that the minimal size of a protein epitope is about four to six amino acids. As is appreciated by those skilled in the art, an epitope can include amino acids that naturally are contiguous to each other as well as amino acids that, due to the tertiary structure of the natural protein, are in sufficiently close proximity to form an epitope. According to the present invention, an epitope includes a portion of a protein comprising at least 4 amino acids, at least 5 amino acids, at least 6 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, at least 25 amino acids, at least 30 amino acids, at least 35 amino acids, at least 40 amino acids or at least 50 amino acids in length.

In one embodiment of the present invention a tick octopamine receptor homologue protein has tick octopamine receptor activity, i.e. the homologue exhibits an activity similar to its natural counterpart, e.g. the ability to bind octopamine. Methods to detect and measure such activities are known to those skilled in the art.

Tick octopamine receptor homologue proteins can be the result of natural allelic variation or natural mutation. Tick octopamine receptor protein homologues of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis.

Tick octopamine receptor proteins of the present invention are encoded by tick octopamine receptor nucleic acid molecules. As used herein, tick octopamine receptor nucleic acid molecules include nucleic acid sequences related to natural tick octopamine

receptor genes, and, preferably, to *R. sanguineus* tick octopamine receptor genes. As used herein, tick octopamine receptor genes include all regions such as regulatory regions that control production of tick octopamine receptor proteins encoded by such genes (such as, but not limited to, transcription, translation or post-translation control regions) as well as the 5 coding region itself, and any introns or non-translated coding regions. As used herein, a nucleic acid molecule that "includes" or "comprises" a sequence may include that sequence in one contiguous array, or may include the sequence as fragmented exons such as is often found for a tick gene. As used herein, the term "coding region" refers to a continuous linear array of nucleotides that translates into a protein. A full-length coding region is that coding 10 region that is translated into a full-length, i.e., a complete protein as would be initially translated in its natural milieu, prior to any post-translational modifications.

One embodiment of the present invention is a *R. sanguineus* tick octopamine receptor gene that includes the nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12 either in a consecutive array or interrupted by naturally occurring introns. These nucleic acid 15 sequences are further described herein. For example, nucleic acid sequence SEQ ID NO:10 represents the deduced sequence of the coding strand of a *R. sanguineus* cDNA denoted herein as *R. sanguineus* octopamine receptor nucleic acid molecule nRsOCR₁₄₄₃, the production of which is disclosed in the Examples. Nucleic acid molecule SEQ ID NO:10 20 comprises an apparently full-length coding region. The complement of SEQ ID NO:10 (represented herein by SEQ ID NO:12) refers to the nucleic acid sequence of the strand fully complementary to the strand having SEQ ID NO:10, which can easily be determined by those skilled in the art. Likewise, a nucleic acid sequence complement of any nucleic acid 25 sequence of the present invention refers to the nucleic acid sequence of the nucleic acid strand that is fully complementary to (i.e., can form a complete double helix with) the strand for which the sequence is cited. It should be noted that since nucleic acid sequencing technology is not entirely error-free, SEQ ID NO:10 (as well as other nucleic acid and

protein sequences presented herein) represents an apparent nucleic acid sequence of the nucleic acid molecule encoding a tick octopamine receptor protein of the present invention.

Translation of SEQ ID NO:10, the coding strand of nRsOCR₁₄₄₃ yields a protein of 480 amino acids, denoted herein as PRsOCR₄₈₀, the amino acid sequence of which is 5 presented in SEQ ID NO:11, assuming an (a) initiation codon extending from nucleotide 1 to 3 of SEQ ID NO:10 and (b) a last codon extending from nucleotide 1 to 1440 of SEQ ID NO:10.

In one embodiment, a gene or other nucleic acid molecule of the present invention can be an allelic variant that includes a similar but not identical sequence to SEQ ID NO:1, 10 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12. For example, an allelic variant of a *R. sanguineus* octopamine receptor gene including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12, is a gene that occurs at essentially the same locus (or loci) in the genome as the gene including SEQ ID NO:1, SEQ ID NO:3, SEQ 15 ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12, but which, due to natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Because natural selection typically selects against alterations that affect function, allelic variants (i.e. alleles corresponding to, or of, cited nucleic acid sequences) usually encode proteins having similar activity to that of the protein 20 encoded by the gene to which they are being compared. Allelic variants of genes or nucleic acid molecules can also comprise alterations in the 5' or 3' untranslated regions of the gene (e.g., in regulatory control regions), or can involve alternative splicing of a nascent transcript, thereby bringing alternative exons into juxtaposition. Allelic variants are well known to those skilled in the art and would be expected to occur naturally within a given tick species, 25 since the genome is diploid, and sexual reproduction will result in the reassortment of alleles.

In one embodiment of the present invention, isolated tick octopamine receptor proteins are encoded by nucleic acid molecules that hybridize under stringent hybridization

conditions to genes or other nucleic acid molecules encoding tick octopamine receptor proteins, respectively. The minimal size of tick octopamine receptor proteins of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid (i.e., hybridizing under stringent hybridization conditions) with the 5 complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. The size of a nucleic acid molecule encoding such a protein is dependent on the nucleic acid composition and the percent homology between the tick octopamine receptor nucleic acid molecule and the complementary nucleic acid sequence. It can easily be understood that the extent of homology required to form a stable hybrid under stringent 10 conditions can vary depending on whether the homologous sequences are interspersed throughout a given nucleic acid molecule or are clustered (i.e., localized) in distinct regions on a given nucleic acid molecule.

The minimal size of a nucleic acid molecule capable of forming a stable hybrid with a gene encoding a tick octopamine receptor protein is at least about 12 to about 15 nucleotides 15 in length if the nucleic acid molecule is GC-rich and at least about 15 to about 17 bases in length if it is AT-rich. The minimal size of a nucleic acid molecule used to encode a tick octopamine receptor protein homologue of the present invention is from about 12 to about 18 nucleotides in length. Thus, the minimal size of tick octopamine receptor protein homologues of the present invention is from about 4 to about 6 amino acids in length. There 20 is no limit, other than a practical limit, on the maximal size of a nucleic acid molecule encoding a tick octopamine receptor protein of the present invention because a nucleic acid molecule of the present invention can include a portion of a gene or cDNA or RNA, an entire gene or cDNA or RNA, or multiple genes or cDNA or RNA. The preferred size of a protein encoded by a nucleic acid molecule of the present invention depends on whether a full-length, fusion, multivalent, or functional portion of such a protein is desired. 25

Stringent hybridization conditions are determined based on defined physical properties of the tick octopamine receptor nucleic acid molecule to which the nucleic acid

molecule is being hybridized, and can be defined mathematically. Stringent hybridization conditions are those experimental parameters that allow an individual skilled in the art to identify significant similarities between heterologous nucleic acid molecules. These conditions are well known to those skilled in the art. See, for example, Sambrook, *et al.*, 5 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, and Meinkoth, *et al.*, 1984, *Anal. Biochem.* 138, 267-284, each of which is incorporated by reference herein in its entirety. As explained in detail in the cited references, the determination of hybridization conditions involves the manipulation of a set of variables including the ionic strength (M, in moles/liter), the hybridization temperature ($^{\circ}\text{C}$), the 10 concentration of nucleic acid helix destabilizing agents (such as formamide), the average length of the shortest hybrid duplex (n), and the percent G + C composition of the fragment to which an unknown nucleic acid molecule is being hybridized. For nucleic acid molecules of at least about 150 nucleotides, these variables are inserted into a standard mathematical formula to calculate the melting temperature, or T_m , of a given nucleic acid molecule. As 15 defined in the formula below, T_m is the temperature at which two complementary nucleic acid molecule strands will disassociate, assuming 100% complementarity between the two strands:

$$T_m = 81.5^{\circ}\text{C} + 16.6 \log M + 0.41(\%G + C) - 500/n - 0.61(\%\text{formamide}).$$

For nucleic acid molecules smaller than about 50 nucleotides, hybrid stability is defined by 20 the dissociation temperature (T_d), which is defined as the temperature at which 50% of the duplexes dissociate. For these smaller molecules, the stability at a standard ionic strength is defined by the following equation:

$$T_d = 4(G + C) + 2(A + T).$$

A temperature of 5 $^{\circ}\text{C}$ below T_d is used to detect hybridization between perfectly matched 25 molecules.

Also well known to those skilled in the art is how base pair mismatch, i.e. differences between two nucleic acid molecules being compared, including non-complementarity of

bases at a given location, and gaps due to insertion or deletion of one or more bases at a given location on either of the nucleic acid molecules being compared, will affect T_m or T_d for nucleic acid molecules of different sizes. For example, T_m decreases about 1°C for each 1% of mismatched base pairs for hybrids greater than about 150 bp, and T_d decreases about 5°C for each mismatched base pair for hybrids below about 50 bp. Conditions for hybrids between about 50 and about 150 base pairs can be determined empirically and without undue experimentation using standard laboratory procedures well known to those skilled in the art. These simple procedures allow one skilled in the art to set the hybridization conditions (by altering, for example, the salt concentration, the formamide concentration or the temperature) so that only nucleic acid hybrids with greater than a specified % base pair mismatch will hybridize. Because one skilled in the art can easily determine whether a given nucleic acid molecule to be tested is less than or greater than about 50 nucleotides, and can therefore choose the appropriate formula for determining hybridization conditions, he or she can determine whether the nucleic acid molecule will hybridize with a given gene under conditions designed to allow a desired amount of base pair mismatch.

Hybridization reactions are often carried out by attaching the nucleic acid molecule to be hybridized to a solid support such as a membrane, and then hybridizing with a labeled nucleic acid molecule, typically referred to as a probe, suspended in a hybridization solution. Examples of common hybridization reaction techniques include, but are not limited to, the well-known Southern and northern blotting procedures. Typically, the actual hybridization reaction is done under non-stringent conditions, i.e., at a lower temperature and/or a higher salt concentration, and then high stringency is achieved by washing the membrane in a solution with a higher temperature and/or lower salt concentration in order to achieve the desired stringency.

For example, if the skilled artisan wished to identify a nucleic acid molecule that hybridizes under conditions that would allow less than or equal to 30% pair mismatch with a tick octopamine receptor nucleic acid molecule of about 150 bp in length or greater, the

following conditions could preferably be used. The average G + C content of tick DNA is about 30%, as calculated from known tick nucleic acid sequences. The unknown nucleic acid molecules would be attached to a support membrane, and the 150 bp probe would be labeled, e.g. with a radioactive tag. The hybridization reaction could be carried out in a
5 solution comprising 2X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of about 37°C (low stringency conditions). Solutions of differing concentrations of SSC can be made by one of skill in the art by diluting a stock solution of 20X SSC (175.3 gram NaCl and about 88.2 gram sodium citrate in 1 liter of water, pH 7) to obtain the desired concentration of SSC. The skilled artisan would calculate the washing
10 conditions required to allow up to 30% base pair mismatch. For example, in a wash solution comprising 1X SSC in the absence of nucleic acid helix destabilizing compounds, the T_m of perfect hybrids would be about 76.8°C:

$$81.5^\circ\text{C} + 16.6 \log (.15\text{M}) + (0.41 \times 30) - (500/150) - (0.61 \times 0) = 76.8^\circ\text{C}.$$

Thus, to achieve hybridization with nucleic acid molecules having about 20% base pair
15 mismatch, hybridization washes would be carried out at a temperature of less than or equal to 56.8°C. It is thus within the skill of one in the art to calculate additional hybridization temperatures based on the desired percentage base pair mismatch, formulae and G/C content disclosed herein. For example, it is appreciated by one skilled in the art that as the nucleic acid molecule to be tested for hybridization against nucleic acid molecules of the present
20 invention having sequences specified herein becomes longer than 150 nucleotides, the T_m for a hybridization reaction allowing up to 20% base pair mismatch will not vary significantly from 56.8°C. Similarly, to achieve hybridization with nucleic acid molecules having about 10% base pair mismatch, hybridization washes would be carried out at a temperature of less than or equal to 66.8°C and to achieve hybridization with nucleic acid molecules having
25 about 5% base pair mismatch, hybridization washes would be carried out at a temperature of less than or equal to 71.8°C.

Furthermore, it is known in the art that there are commercially available computer programs for determining the degree of similarity between two nucleic acid or protein sequences. These computer programs include various known methods to determine the percentage identity and the number and length of gaps between hybrid nucleic acid molecules or proteins. Preferred methods to determine the percent identity among amino acid sequences and also among nucleic acid sequences include analysis using one or more of the commercially available computer programs designed to compare and analyze nucleic acid or amino acid sequences. These computer programs include, but are not limited to, the SeqLab® Wisconsin Package™ Version 10.0-UNIX sequence analysis software, available from Genetics Computer Group, Madison, WI (hereinafter "SeqLab"); and DNAsis® sequence analysis software, version 2.0, available from Hitachi Software, San Bruno, CA (hereinafter "DNAsis"). Such software programs represent a collection of algorithms paired with a graphical user interface for using the algorithms. The DNAsis and SeqLab software, for example, employ a particular algorithm, the Needleman-Wunsch algorithm to perform pair-wise comparisons between two sequences to yield a percentage identity score, see Needleman, S.B. and Wunch, C.D., 1970, *J. Mol. Biol.*, 48, 443, which is incorporated herein by reference in its entirety. Such algorithms, including the Needleman-Wunsch algorithm, are commonly used by those skilled in the nucleic acid and amino acid sequencing art to compare sequences. A preferred method to determine percent identity among amino acid sequences and also among nucleic acid sequences includes using the Needleman-Wunsch algorithm, available in the SeqLab software, using the Pairwise Comparison/Gap function with the nwsgapdna.cmp scoring matrix, the gap creation penalty and the gap extension penalties set at default values, and the gap shift limits set at maximum (hereinafter referred to as "SeqLab default parameters"). An additional preferred method to determine percent identity among amino acid sequences and also among nucleic acid sequences includes using the Higgins-Sharp algorithm, available in the DNAsis software (hereinafter "DNAsis"), with the gap penalty set at 5, the number of top diagonals set at 5, the fixed gap penalty set at 10,

the k-tuple set at 2, the window size set at 5, and the floating gap penalty set at 10. A particularly preferred method to determine percent identity among amino acid sequences and also among nucleic acid sequences includes using the Needleman-Wunsch algorithm available in the SeqLab software, using the SeqLab default parameters.

5 One embodiment of the present invention includes a tick octopamine receptor protein. A preferred tick octopamine receptor protein includes a protein encoded by a nucleic acid molecule that hybridizes under conditions that preferably allow less than or equal to 30% base pair mismatch, preferably under conditions that allow less than or equal to 20% base pair mismatch, preferably under conditions that allow less than or equal to 10% base pair mismatch, preferably under conditions that allow less than or equal to 8% base pair mismatch, preferably under conditions that allow less than or equal to 5% base pair mismatch or preferably under conditions that allow less than or equal to 2% base pair mismatch with a nucleic acid molecule selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12.

15 Another embodiment of the present invention includes a tick octopamine receptor protein encoded by a nucleic acid molecule that hybridizes under conditions comprising, (a) hybridizing in a solution comprising 1X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of 37°C and (b) washing in a solution comprising 1X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of 20 66.8°C, to an isolated nucleic acid molecule selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12.

Another preferred tick octopamine receptor protein of the present invention includes a protein that is encoded by a nucleic acid molecule that is preferably at least 70%, preferably at least 80%, preferably at least 90% identical, preferably at least 92% identical, preferably at least 95% identical or preferably at least 98% identical to a nucleic acid molecule having the nucleic acid sequence SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10; also preferred are fragments (i.e. portions) of such proteins encoded by nucleic acid molecules

that are at least 50 nucleotides. Percent identity as used herein is determined using the Needleman-Wunsch algorithm, available in the SeqLab software using default parameters.

Additional preferred tick octopamine receptor proteins of the present invention include proteins having the amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, and proteins comprising homologues of a protein having the amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, wherein such a homologue comprises at least one epitope that elicits an immune response against a protein having an amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11. Likewise, also preferred are proteins encoded by nucleic acid molecules comprising nucleic acid sequence SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10, or by homologues thereof.

A preferred isolated tick octopamine receptor protein of the present invention is a protein encoded by at least one of the following nucleic acid molecules: nRsOCR₁₀₂, nRsOCR₄₉₉, nRsOCR₂₈₆, and nRsOCR₁₄₄₃, or allelic variants of any of these nucleic acid molecules. Also preferred is an isolated protein encoded by a nucleic acid molecule having nucleic acid sequence SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10; or a protein encoded by an allelic variant of any of these listed nucleic acid molecules.

Preferred tick octopamine receptor proteins of the present invention include proteins having amino acid sequences that are at least 70%, preferably 80%, preferably 90%, preferably 95%, preferably at least 98%, preferably at least 99%, or preferably 100% identical to amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11; and proteins encoded by allelic variants of nucleic acid molecules encoding tick octopamine receptor proteins having amino acid sequences SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.

Preferred tick octopamine receptor proteins of the present invention include proteins selected from the group consisting of (a) a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ

ID NO:11; and (b) a protein comprising an at least 20 contiguous amino acid portion identical in sequence to an at least 20 contiguous amino acid portion of an amino acid sequence of (a).

In one embodiment of the present invention, *R. sanguineus* octopamine receptor proteins comprise amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11 (including, but not limited to, the proteins consisting of amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, fusion proteins and multivalent proteins), and proteins encoded by allelic variants of nucleic acid molecules encoding proteins having amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.

In one embodiment, a preferred tick octopamine receptor protein comprises an amino acid sequence of at least 30 amino acids, preferably at least 35 amino acids, preferably at least 75 amino acids, preferably at least 95 amino acids, preferably at least 150 amino acids, preferably at least 200 amino acids, preferably at least 300 amino acids, preferably at least 400 amino acids, preferably at least 450 amino acids, preferably at least 475 amino acids, or preferably at least 480 amino acids. In another embodiment, preferred tick octopamine receptor proteins comprise full-length proteins, i.e., proteins encoded by full-length coding regions, or post-translationally modified proteins thereof, such as mature proteins from which initiating methionine and/or signal sequences or "pro" sequences have been removed.

Also preferred are tick octopamine receptor proteins encoded by nucleic acid molecules having nucleic acid sequences comprising at least a portion of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10, as well as allelic variants of these nucleic acid molecules. A portion of such tick octopamine receptor nucleic acid molecule is preferably at least 50 nucleotides in length.

In another embodiment, a preferred tick octopamine receptor protein of the present invention is encoded by a nucleic acid molecule comprising at least 30 nucleotides, preferably at least 50 nucleotides, preferably at least 75 nucleotides, preferably at least 100

nucleotides, preferably at least 150 nucleotides, preferably at least 250 nucleotides, preferably at least 500 nucleotides, preferably at least 750 nucleotides, preferably at least 1000 nucleotides, preferably at least 1250 nucleotides, preferably at least 1400 nucleotides or preferably at least 1440 nucleotides in length that bind octopamine. Preferred tick 5 octopamine receptor proteins of the present invention are encoded by nucleic acid molecules comprising apparently full-length tick octopamine receptor coding region, i.e., nucleic acid molecules encoding an apparently full-length tick octopamine receptor protein, or extracellular domain.

Preferred tick octopamine receptor proteins of the present invention can be used to 10 develop inhibitors that, when administered to an animal in an effective manner, are capable of protecting that animal from tick infestation. In accordance with the present invention, the ability of an inhibitor of the present invention to protect an animal from tick infestation refers to the ability of that inhibitor to, for example, treat, ameliorate and/or prevent infestation caused by ticks. In particular, the phrase "to protect an animal from tick infestation" refers to 15 reducing the potential for tick population expansion on and around the animal (i.e., reducing the tick burden). Preferably, the tick population size is decreased, optimally to an extent that the animal is no longer bothered by ticks. A host animal, as used herein, is an animal from which ticks can feed by attaching to and feeding through the skin of the animal. Ticks, and other ectoparasites, can live on a host animal for an extended period of time or can attach 20 temporarily to an animal in order to feed. At any given time, a certain percentage of a tick population can be on a host animal whereas the remainder can be in the environment of the animal. Such an environment can include not only adult ticks, but also tick eggs and/or tick larvae. The environment can be of any size such that ticks in the environment are able to 25 jump onto and off of a host animal. For example, the environment of an animal can include plants, such as crops, from which ticks infest an animal. As such, it is desirable not only to reduce the tick burden on an animal per se, but also to reduce the tick burden in the environment of the animal.

Suitable ticks to target include any tick that is essentially incapable of causing disease in an animal administered an inhibitor of the present invention. As such, ticks to target include any tick that produces a protein that can be targeted by an inhibitory compound that inhibits a tick tick octopamine receptor protein function, thereby resulting in the decreased 5 ability of the parasite to cause disease in an animal. Preferred ticks to target include ticks of the following genera: *Amblyomma*, *Dermacentor*, *Ixodes* and *Rhipicephalus*, with those of the species *Amblyomma americanum*, *Amblyomma maculatum*, *Dermacentor albipictus*, *Dermacentor andersoni*, *Dermacentor variabilis*, *Ixodes scapularis* and *Rhipicephalus sanguineus* being more preferred. Such ticks are also preferred for the isolation of proteins 10 or nucleic acid molecules of the present invention.

Another embodiment of the present invention is an isolated nucleic acid molecule comprising a tick octopamine receptor nucleic acid molecule, i.e. a nucleic acid molecule that can be isolated from a tick cDNA library. The identifying characteristics of such nucleic acid molecules are heretofore described. A nucleic acid molecule of the present invention can 15 include an isolated natural tick octopamine receptor gene or a homologue thereof, the latter of which is described in more detail below. A nucleic acid molecule of the present invention can include one or more regulatory regions, full-length or partial coding regions, or combinations thereof. The minimal size of a nucleic acid molecule of the present invention is a size sufficient to allow the formation of a stable hybrid (i.e., hybridization under stringent 20 hybridization conditions) with the complementary sequence of another nucleic acid molecule. As such, the minimal size of a tick octopamine receptor nucleic acid molecule of the present invention is from 12 to 18 nucleotides in length.

In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been 25 subjected to human manipulation) and can include DNA, RNA, or derivatives of either DNA or RNA. As such, "isolated" does not reflect the extent to which the nucleic acid molecule has been purified. Isolated tick octopamine receptor nucleic acid molecules of the present

invention, or homologues thereof, can be isolated from a natural source or produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification or cloning) or chemical synthesis. Isolated tick octopamine receptor nucleic acid molecules, and homologues thereof, can include, for example, natural allelic variants and nucleic acid molecules modified by nucleotide insertions, deletions, substitutions, and/or inversions in a manner such that the modifications do not substantially interfere with the nucleic acid molecule's ability to encode a tick octopamine receptor protein of the present invention.

A tick octopamine receptor nucleic acid molecule homologue can be produced using a number of methods known to those skilled in the art, see, for example, Sambrook et al., 10 *ibid.*, which is incorporated by reference herein in its entirety. For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis and recombinant DNA techniques such as site-directed mutagenesis, chemical treatment, restriction enzyme cleavage, ligation of nucleic acid fragments, PCR amplification, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" 15 a mixture of nucleic acid molecules, and combinations thereof. Nucleic acid molecule homologues can be selected by hybridization with tick octopamine receptor nucleic acid molecules or by screening the function of a protein encoded by the nucleic acid molecule (e.g., ability to elicit an immune response against at least one epitope of a tick octopamine receptor protein or to effect tick octopamine receptor activity).

An isolated tick octopamine receptor nucleic acid molecule of the present invention 20 can include a nucleic acid sequence that encodes at least one tick octopamine receptor protein of the present invention respectively, examples of such proteins being disclosed herein. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of 25 nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a tick octopamine receptor protein.

In one embodiment of the present invention, a preferred tick octopamine receptor nucleic acid molecule includes an isolated nucleic acid molecule that hybridizes under conditions that preferably allow less than or equal to 30% base pair mismatch, preferably under conditions that allow less than or equal to 20% base pair mismatch, preferably under 5 conditions that allow less than or equal to 10% base pair mismatch, preferably under conditions that allow less than or equal to 8% base pair mismatch, preferably under conditions that allow less than or equal to 5% base pair mismatch or preferably under conditions that allow less than or equal to 2% base pair mismatch with a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, 10 SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

One embodiment of the present invention includes a tick octopamine receptor nucleic acid molecule, wherein said nucleic acid molecule hybridizes under conditions comprising, (a) hybridizing in solution comprising 1X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of 37°C and (b) washing in a solution comprising 15 1X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of 74.6°C, to an isolated nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

Additional preferred tick octopamine receptor nucleic acid molecules of the present 20 invention include nucleic acid molecules comprising a nucleic acid sequence at least 50 nucleotides in length that is preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 92%, preferably at least 95%, or preferably at least 98% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10 and encodes a protein that binds 25 octopamine.

One preferred nucleic acid molecule of the present invention includes at least a portion of nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID

NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12, as well as allelic variants of nucleic acid molecules having these nucleic acid sequences and homologues of nucleic acid molecules having these nucleic acid sequences; preferably such a homologue encodes or is complementary to a nucleic acid molecule that encodes at least one epitope that
5 elicits an immune response against a protein having an amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11. Such nucleic acid molecules can include nucleotides in addition to those included in the SEQ ID NOs, such as, but not limited to, a full-length gene, a full-length coding region, a nucleic acid molecule encoding a fusion protein, or a nucleic acid molecule encoding a multivalent protective compound.

10 One embodiment of the present invention is a nucleic acid molecule comprising an isolated nucleic acid molecule having a nucleic acid sequence selected from the group consisting of: (a) a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12; and (b) a nucleic acid molecule having an at least 50 contiguous
15 nucleotide portion identical in sequence to an at least 50 contiguous nucleotide portion of a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

In one embodiment, a tick octopamine receptor nucleic acid molecule of the present
20 invention encodes a protein having an amino acid sequence that is at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%, or preferably at least 100% identical to SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11. The present invention also includes a tick octopamine receptor nucleic acid molecule encoding a protein having at least a portion of
25 SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, as well as allelic variants of a nucleic acid molecule encoding a protein having these sequences, including nucleic acid

molecules that have been modified to accommodate codon usage properties of the cells in which such nucleic acid molecules are to be expressed.

In another embodiment, a preferred tick octopamine receptor nucleic acid molecule of the present invention comprises a nucleic acid molecule comprising at least 30 nucleotides, 5 preferably at least 50 nucleotides, preferably at least 75 nucleotides, preferably at least 100 nucleotides, preferably at least 150 nucleotides, preferably at least 250 nucleotides, preferably at least 500 nucleotides, preferably at least 750 nucleotides, preferably at least 1000 nucleotides, preferably at least 1250 nucleotides, preferably at least 1400 nucleotides or preferably at least 1440 nucleotides in length and encodes a protein that binds octopamine.

10 In another embodiment, a preferred tick octopamine receptor nucleic acid molecule encodes a protein comprising at least 30 amino acids, preferably at least 35 amino acids, preferably at least 75 amino acids, preferably at least 95 amino acids, preferably at least 150 amino acids, preferably at least 200 amino acids, preferably at least 300 amino acids, preferably at least 400 amino acids, preferably at least 450 amino acids, preferably at least 15 475 amino acids, or preferably at least 480 amino acids.

In another embodiment, a preferred tick octopamine receptor nucleic acid molecule of the present invention comprises an apparently full-length tick octopamine receptor coding region, i.e., the preferred nucleic acid molecule encodes an apparently full-length tick octopamine receptor protein, respectively, or a post-translationally modified protein thereof.

20 In one embodiment, a preferred tick octopamine receptor nucleic acid molecule of the present invention encodes a mature protein or extracellular domain.

In another embodiment, a preferred tick octopamine receptor nucleic acid molecule of the present invention comprises a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and 25 SEQ ID NO:12, or a fragment thereof.

A tick octopamine receptor nucleic acid molecule of the present invention preferably comprises at least 30 nucleotides, preferably at least 50 nucleotides, preferably at least 75

nucleotides, preferably at least 100 nucleotides, preferably at least 150 nucleotides, preferably at least 250 nucleotides, preferably at least 500 nucleotides, preferably at least 750 nucleotides, preferably at least 1000 nucleotides, preferably at least 1250 nucleotides, preferably at least 1400 nucleotides or preferably at least 1440 nucleotides identical in sequence to a corresponding contiguous sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

- The phrase, a nucleic acid molecule comprising at least "x" contiguous, or consecutive nucleotides identical in sequence to at least "x" contiguous, or consecutive nucleotides of a nucleic acid molecule selected from the group consisting of SEQ ID NO:"y", refers to an "x"-nucleotide in length nucleic acid molecule that is identical in sequence to an "x"-nucleotide portion of SEQ ID NO:"y", as well as to nucleic acid molecules that are longer in length than "x". The additional length may be in the form of nucleotides that extend from either the 5' or the 3' end(s) of the contiguous identical "x"-nucleotide portion.
- 15 The 5' and/or 3' extensions can include one or more extensions that have no identity to a molecule of the present invention, as well as extensions that show similarity or identity to cited nucleic acids sequences or portions thereof.

Knowing the nucleic acid sequences of certain tick octopamine receptor nucleic acid molecules of the present invention allows one skilled in the art to, for example, (a) make copies of those nucleic acid molecules, (b) obtain nucleic acid molecules including at least a portion of such nucleic acid molecules (e.g., nucleic acid molecules including full-length genes, full-length coding regions, regulatory control sequences, truncated coding regions), and (c) obtain other tick octopamine receptor nucleic acid molecules. Such nucleic acid molecules can be obtained in a variety of ways including screening appropriate expression libraries with antibodies of the present invention; traditional cloning techniques using oligonucleotide probes of the present invention to screen appropriate libraries; and PCR amplification of appropriate libraries or DNA using oligonucleotide primers of the present

invention. Preferred libraries to screen or from which to amplify nucleic acid molecules include cDNA libraries as well as genomic DNA libraries. Similarly, preferred DNA sources to screen or from which to amplify nucleic acid molecules include cDNA and genomic DNA. Techniques to clone and amplify genes are disclosed, for example, in Sambrook et al., *ibid.*

5 One embodiment of the present invention includes a recombinant vector, which includes at least one isolated nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a host cell. Such a vector contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not naturally found adjacent to nucleic acid molecules of the present invention and that
10 preferably are derived from a species other than the species from which the nucleic acid molecule(s) are derived. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of tick octopamine receptor nucleic acid molecules of the present invention.

15 One type of recombinant vector, referred to herein as a recombinant molecule, comprises a nucleic acid molecule of the present invention operatively linked to an expression vector. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA
20 vector that is capable of transforming a host cell and of effecting expression of a specified nucleic acid molecule. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in recombinant cells of the present invention, including
25 in bacterial, fungal, parasite, insect, other animal, and plant cells. Preferred expression vectors of the present invention can direct gene expression in bacterial, yeast, insect and mammalian cells, and more preferably in the cell types disclosed herein.

In particular, expression vectors of the present invention contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of nucleic acid molecules of the present invention. In particular, recombinant 5 molecules of the present invention include transcription control sequences. Transcription control sequences are sequences that control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences.

Suitable transcription control sequences include any transcription control sequence that can 10 function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those that function in bacterial, yeast, or insect and mammalian cells, such as, but not limited to, *tac*, *lac*, *trp*, *trc*, oxy-pro, *omp/lpp*, *rrnB*, bacteriophage lambda (such as lambda p_L and lambda p_R and fusions that include such promoters), 15 bacteriophage T7, T7*lac*, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, *Pichia* alcohol oxidase, alphavirus subgenomic promoter, antibiotic resistance gene, baculovirus, *Heliothis zea* insect virus, vaccinia virus, herpesvirus, raccoon poxvirus, other poxvirus, adenovirus, cytomegalovirus (such as immediate early promoter), simian virus 40, retrovirus, actin, retroviral long terminal repeat, 20 Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and 25 enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins). Transcription control sequences of the present invention can also include naturally occurring transcription control sequences naturally associated with ticks, such as *R. sanguineus* transcription control sequences. Suitable and preferred nucleic acid molecules to include in recombinant vectors of the present invention are as disclosed herein.

Recombinant molecules of the present invention may also (a) contain secretory signals (i.e., signal segment nucleic acid sequences) to enable an expressed tick octopamine receptor protein of the present invention to be secreted from the cell that produces the protein and/or (b) contain fusion sequences which lead to the expression of nucleic acid molecules of the present invention as fusion proteins. Examples of suitable signal segments include any signal segment capable of directing the secretion of a protein of the present invention.

Preferred signal segments include, but are not limited to, tissue plasminogen activator (t-PA), interferon, interleukin, growth hormone, histocompatibility and viral envelope glycoprotein signal segments. Suitable fusion segments encoded by fusion segment nucleic acids are disclosed herein. In addition, a nucleic acid molecule of the present invention can be joined to a fusion segment that directs the encoded protein to the proteosome, such as a ubiquitin fusion segment. Eukaryotic recombinant molecules may also include intervening and/or untranslated sequences surrounding and/or within the nucleic acid sequences of nucleic acid molecules of the present invention.

Another embodiment of the present invention includes a recombinant cell comprising a host cell transformed with one or more recombinant molecules of the present invention. Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. It is to be noted that a cell line refers to any recombinant cell of the present invention that is not a transgenic animal. Transformed nucleic acid molecules of the present invention can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained. Preferred nucleic acid molecules with which to transform a cell include tick octopamine receptor nucleic acid molecules disclosed herein.

Suitable host cells to transform include any cell that can be transformed with a nucleic acid molecule of the present invention. Host cells can be either untransformed cells or cells that are already transformed with at least one nucleic acid molecule (e.g., nucleic acid molecules encoding one or more proteins of the present invention and/or other proteins useful in the production of multivalent vaccines). Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing tick octopamine receptor proteins of the present invention or can be capable of producing such proteins after being transformed with at least one nucleic acid molecule of the present invention. Host cells of the present invention can be any cell capable of producing at least one protein of the present invention, and include bacterial, fungal (including yeast), parasite (including helminth, protozoa and ectoparasite), other insect, other animal and plant cells. Preferred host cells include bacterial, mycobacterial, yeast, insect and mammalian cells. More preferred host cells include *Drosophila melanogaster* S2 cells, *Salmonella*, *Escherichia*, *Bacillus*, *Caulobacter*, *Listeria*, *Saccharomyces*, *Pichia*, *Spodoptera*, *Mycobacteria*, *Trichoplusia*, BHK (baby hamster kidney) cells, MDCK cells (Madin-Darby canine kidney cell line), CRFK cells (Crandell feline kidney cell line), CV-1 cells (African monkey kidney cell line used, for example, to culture raccoon poxvirus), COS (e.g., COS-7) cells, and Vero cells. Particularly preferred host cells are *Escherichia coli*, including *E. coli* K-12 derivatives; *Salmonella typhi*; *Salmonella typhimurium*, including attenuated strains such as UK-1 χ 3987 and SR-11 χ 4072; *Caulobacter*; *Pichia*; *Spodoptera frugiperda*; *Trichoplusia ni*; BHK cells; MDCK cells; CRFK cells; CV-1 cells; COS cells; Vero cells; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246). Additional appropriate mammalian cell hosts include other kidney cell lines, other fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines), myeloma cell lines, Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK³¹ cells and/or HeLa cells. In one embodiment, the proteins may be expressed as heterologous proteins in myeloma cell lines employing immunoglobulin promoters.

A recombinant cell is preferably produced by transforming a host cell with one or more recombinant molecules, each comprising one or more nucleic acid molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences, examples of which are disclosed herein. The phrase 5 operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell.

A recombinant cell of the present invention includes any cell transformed with at least one of any nucleic acid molecule of the present invention. Suitable and preferred nucleic acid molecules as well as suitable and preferred recombinant molecules with which 10 to transfer cells are disclosed herein.

Recombinant cells of the present invention can also be co-transformed with one or more recombinant molecules including tick octopamine receptor nucleic acid molecules encoding one or more proteins of the present invention and one or more other nucleic acid molecules encoding other protective compounds, as disclosed herein (e.g., to produce 15 multivalent vaccines).

Recombinant DNA technologies can be used to improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the 20 efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals 25 (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell,

deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein.

Isolated tick octopamine receptor proteins of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an isolated protein of the present invention is produced by culturing a cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. A preferred cell to culture is a recombinant cell of the present invention. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective, medium refers to any medium in which a cell is cultured to produce a tick octopamine receptor protein of the present invention. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art. Examples of suitable conditions are included in the Examples section.

Depending on the vector and host system used for production, resultant proteins of the present invention may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the periplasmic space in *E. coli*; or be retained on the outer surface of a cell or viral membrane.

The phrase "recovering the protein", as well as similar phrases, refers to collecting the whole fermentation medium containing the protein and need not imply additional steps of

separation or purification. Proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin 5 chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein as a therapeutic composition or diagnostic. A therapeutic composition for animals, for example, should exhibit no substantial toxicity and preferably should be capable of stimulating the production 10 of antibodies in a treated animal.

The present invention also includes isolated (i.e., removed from their natural milieu) antibodies that selectively bind to a tick octopamine receptor protein of the present invention or a mimotope thereof (e.g., anti-tick octopamine receptor antibodies). As used herein, the term "selectively binds to" a protein refers to the ability of antibodies of the present invention 15 to preferentially bind to specified proteins and mimotopes thereof of the present invention. Binding can be measured using a variety of methods standard in the art including enzyme immunoassays (e.g., ELISA), immunoblot assays, etc.; see, for example, Sambrook et al., *ibid.*, and Harlow, et al., 1988, *Antibodies, a Laboratory Manual*, Cold Spring Harbor Labs Press; Harlow et al., *ibid.*, is incorporated by reference herein in its entirety. An anti-tick 20 octopamine receptor antibody of the present invention preferably selectively binds to a tick octopamine receptor protein, respectively, in such a way as to inhibit the function of that protein.

Isolated antibodies of the present invention can include antibodies in serum, or antibodies that have been purified to varying degrees. Antibodies of the present invention 25 can be polyclonal or monoclonal, or can be functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies or chimeric antibodies that can bind to one or more epitopes.

One embodiment of the present invention is a therapeutic composition that, when administered to an animal susceptible to tick infestation, is capable of protecting that animal from tick infestation. Therapeutic compositions of the present invention include at least one of the following protective molecules: an isolated tick octopamine receptor protein; a mimotope of an isolated tick octopamine receptor protein; an isolated tick octopamine receptor nucleic acid molecule; and/or a compound derived from said isolated tick octopamine receptor protein that inhibits tick octopamine receptor protein activity, an anti-tick octopamine receptor antibody, and/or a compound that inhibits tick octopamine receptor activity. A therapeutic composition of the present invention can further comprise a component selected from the group of an excipient, a carrier, and/or an adjuvant; these components are described further herein. As used herein, a protective molecule or protective compound refers to a compound that, when administered to an animal in an effective manner, is able to treat, ameliorate, and/or prevent tick infestation. Preferred ticks to target are heretofore disclosed. One example of a protective molecule is a vaccine or therapy, such as, but not limited to, a naked nucleic acid vaccine or therapy, a recombinant virus vaccine or therapy, a recombinant cell vaccine or therapy, and a recombinant protein vaccine or therapy. Another example of a protective molecule is a compound that inhibits tick octopamine receptor protein activity, such as an isolated antibody that selectively binds to a tick octopamine receptor protein, a substrate analog of a tick octopamine receptor protein, anti-sense-, triplex formation-, ribozyme-, and/or RNA drug-based compounds, or other inorganic or organic molecules that inhibit tick octopamine receptor protein activity. Inhibiting tick octopamine receptor protein activity can refer to the ability of a compound to reduce the activity of tick octopamine receptor proteins. Inhibiting tick octopamine receptor protein activity can also refer to the ability of a compound to reduce the amount of tick octopamine receptor protein in a tick.

Another embodiment of the present invention includes a method to reduce tick infestation in an animal susceptible to tick infestation. Such a method includes the step of

administering to the animal a therapeutic molecule comprising a protective compound selected from the group consisting of (a) an isolated tick octopamine receptor protein; (b) a mimotope of an isolated tick octopamine receptor protein; (c) an isolated tick octopamine receptor nucleic acid molecule; and (d) a compound derived from an isolated tick octopamine receptor protein that inhibits tick octopamine receptor protein activity.

As used herein, the term derived, or the term derived from, refers to a peptide, antibody, mimotope, nucleic acid molecule, or other compound that was obtained directly or indirectly from a tick octopamine receptor protein or nucleic acid molecule of the present invention, e.g. a part of a protein or nucleic acid molecule or produced using a protein or nucleic acid molecule of the present invention. Methods to obtain derivatives from a tick octopamine receptor molecule of the present invention are known in the art, and as such include, but are not limited to molecular modeling of tick octopamine receptor proteins to determine active sites, and predicting from these active sites smaller fragments and/or mimotopes that retain and/or mimic these active sites, thereby inhibiting tick octopamine receptor protein activity. Other inhibitors of tick octopamine receptor activity can also be obtained in a variety of ways, including but not limited to screening of peptide or small chemical compound libraries against tick octopamine receptor proteins of the present invention; and screening of polyclonal or monoclonal antibodies to find antibodies that specifically bind tick octopamine receptor proteins of the present invention.

A tick octopamine receptor protein inhibitor of the present invention (i.e. an inhibitor of a tick octopamine receptor protein) is identified by its ability to mimic, bind to, modify, or otherwise interact with, a tick octopamine receptor protein, thereby inhibiting the activity of a natural tick octopamine receptor protein. Suitable inhibitors of tick octopamine receptor protein activity are compounds that can inhibit tick octopamine receptor protein activity in at least one of a variety of ways: (a) by binding to or otherwise interacting with or otherwise modifying tick octopamine receptor protein sites; (b) by binding to or otherwise interacting with or otherwise modifying tick octopamine receptor protein active site(s); (c) by binding to

the tick octopamine receptor protein and thus reducing the availability of the tick octopamine receptor protein in solution; (d) by mimicking a tick octopamine receptor protein; and (e) by interacting with other regions of the tick octopamine receptor protein to inhibit tick octopamine receptor protein activity, for example, by allosteric interaction.

5 Tick octopamine receptor protein inhibitors can be used directly as compounds in compositions of the present invention to treat animals as long as such compounds are not harmful to host animals being treated. Preferred tick octopamine receptor protein inhibitors of the present invention include, but are not limited to, tick octopamine receptor protein substrate analogs, and other molecules that bind to a tick octopamine receptor protein (e.g., to
10 an allosteric site) in such a manner that the activity of the tick octopamine receptor protein is inhibited. A tick octopamine receptor protein substrate analog refers to a compound that interacts with (e.g., binds to, associates with, modifies) the active site of a tick octopamine receptor protein. A preferred tick octopamine receptor protein substrate analog inhibits tick octopamine receptor protein activity. Tick octopamine receptor protein substrate analogs can
15 be of any inorganic or organic composition. Tick octopamine receptor protein substrate analogs can be, but need not be, structurally similar to a tick octopamine receptor protein natural substrate as long as they can interact with the active site of that tick octopamine receptor protein. Tick octopamine receptor protein substrate analogs can be designed using computer-generated structures of tick octopamine receptor proteins of the present invention
20 or computer structures of tick octopamine receptor protein's natural substrates. Preferred sites to model include one or more of the active sites of tick octopamine receptor proteins. Substrate analogs can also be obtained by generating random samples of molecules, such as
25 oligonucleotides, peptides, peptidomimetic compounds, or other inorganic or organic molecules, and screening such samples for their ability to interfere with interaction between tick octopamine receptor proteins and their substrates, e.g. by affinity chromatography techniques. A preferred tick octopamine receptor protein substrate analog is a tick octopamine receptor protein mimetic compound, i.e., a compound that is structurally and/or

functionally similar to a natural substrate of a tick octopamine receptor protein of the present invention, particularly to the region of the substrate that interacts with the tick octopamine receptor protein active site, but that inhibits tick octopamine receptor protein activity upon interacting with the tick octopamine receptor protein active site.

5 The present invention also includes a therapeutic composition comprising at least one protective molecule of the present invention in combination with at least one additional compound protective against one or more infectious agents and/or infestation by one or more ectoparasites.

In one embodiment, a therapeutic composition of the present invention can be used to
10 protect an animal from tick infestation by administering such composition to a tick in order to prevent infestation. Such administration to the tick and/or animal could be oral, or by application to the animal's body surface (e.g. topical spot-on, or spraying onto the animal), or by application to the environment (e.g., spraying). Examples of such compositions include, but are not limited to, transgenic vectors capable of producing at least one therapeutic
15 composition of the present invention. In another embodiment a tick can ingest therapeutic compositions, or products thereof, present on the surface of or in the blood of a host animal that has been administered a therapeutic composition of the present invention.

In accordance with the present invention, a host animal (i.e., an animal that is or is capable of being infested with ticks) is treated by administering to the animal a therapeutic
20 composition of the present invention in such a manner that the composition itself (e.g., a tick octopamine receptor protein inhibitor, a octopamine receptor protein synthesis suppressor (i.e., a compound that decreases the production or half-life of a octopamine receptor protein in ticks), a tick octopamine receptor protein mimotope, or a anti-tick octopamine receptor antibody) or a product generated by the animal in response to administration of the
25 composition (e.g., antibodies produced in response to administration of a tick octopamine receptor protein or nucleic acid molecule, or conversion of an inactive inhibitor "prodrug" to an active tick octopamine receptor protein inhibitor) ultimately enters the tick. A host animal

is preferably treated in such a way that the compound or product thereof is present on the body surface of the animal or enters the blood stream of the animal. Ticks are then exposed to the composition or product when they feed from the animal. For example, tick octopamine receptor protein inhibitors administered to an animal are administered in such a 5 way that the inhibitors enter the blood stream of the animal, where they can be taken up by feeding ticks or are administered to the animal topically, where they can be taken up by contact with the treated animal.

In accordance with the present invention, reducing tick octopamine receptor protein activity in a tick can lead to a number of outcomes that reduce tick burden on treated animals 10 and their surrounding environments. Such outcomes include, but are not limited to, (a) reducing the viability of ticks that feed from the treated animal, (b) reducing the fecundity of female ticks that feed from the treated animal, (c) reducing the reproductive capacity of male ticks that feed from the treated animal, (d) reducing the viability of eggs laid by female ticks that feed from the treated animal, (e) altering the blood feeding behavior of ticks that feed 15 from the treated animal (e.g., ticks take up less volume per feeding or feed less frequently), (f) reducing the viability of tick larvae, for example due to the feeding of larvae from feces of ticks that feed from the treated animal, (g) altering the development of tick larvae (e.g., by decreasing feeding behavior, inhibiting growth, inhibiting (e.g., slowing or blocking) molting, and/or otherwise inhibiting maturation to adults), and/or (h) altering or decreasing 20 the ability of ticks or tick larvae to digest a blood meal.

In order to protect an animal from tick infestation, a therapeutic composition of the present invention is administered to the animal in an effective manner such that the composition is capable of protecting that animal from tick infestation. Therapeutic compositions of the present invention can be administered to animals prior to infestation in 25 order to prevent infestation (i.e., as a preventative vaccine) and/or can be administered to animals after infestation (i.e. as a therapy).

Therapeutic compositions of the present invention can be formulated in an excipient that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal, or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.

In one embodiment of the present invention, a therapeutic composition can include an adjuvant. Adjuvants are agents that are capable of enhancing the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, cytokines, chemokines, and compounds that induce the production of cytokines and chemokines (e.g., granulocyte macrophage colony stimulating factor (GM-CSF), Flt-3 ligand, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interferon gamma, interferon gamma inducing factor I (IGIF), transforming growth factor beta, RANTES (regulated upon activation, normal T cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), and Leishmania elongation initiating factor (LEIF)); bacterial components (e.g., endotoxins, in particular superantigens, exotoxins and cell wall components); aluminum-based salts; calcium-based salts; silica; polynucleotides;

toxoids; serum proteins, viral coat proteins; block copolymer adjuvants (e.g., Hunter's Titermax™ adjuvant (Vaxcel™, Inc. Norcross, GA), Ribi adjuvants (Ribi ImmunoChem Research, Inc., Hamilton, MT); and saponins and their derivatives (e.g., Quil A (Superfos Biosector A/S, Denmark). Protein adjuvants of the present invention can be delivered in the form of the protein themselves or of nucleic acid molecules encoding such proteins using the methods described herein.

In one embodiment of the present invention, a therapeutic composition can include a carrier. Carriers include compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, other cells, oils, esters, and glycols.

One embodiment of the present invention is a controlled release formulation that is capable of slowly releasing a composition of the present invention into an animal. As used herein, a controlled release formulation comprises a composition of the present invention in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release formulations of the present invention include liquids that, upon administration to an animal, form a solid or a gel *in situ*. Preferred controlled release formulations are biodegradable (i.e., bioerodible).

A preferred controlled release formulation of the present invention is capable of releasing a composition of the present invention into the blood of the treated animal at a constant rate sufficient to attain therapeutic dose levels of the composition. The therapeutic composition is preferably released over a period of time ranging from about 1 to about 12 months. A controlled release formulation of the present invention is capable of effecting a treatment preferably for at least 1 month, more preferably for at least 3 months, even more

preferably for at least 6 months, even more preferably for at least 9 months, and even more preferably for at least 12 months.

The efficacy of a therapeutic composition of the present invention to protect an animal from tick infestation can be tested in a variety of ways including, but not limited to challenge of the treated animal with the ticks to determine whether the treated animal is resistant to infestation. Challenge studies can include direct administration of ticks to the treated animal. In one embodiment, therapeutic compositions can be tested in animal models such as mice. Such techniques are known to those skilled in the art.

As discussed herein, one therapeutic composition of the present invention includes an inhibitor of tick octopamine receptor protein activity, i.e., a compound capable of substantially interfering with the function of a tick octopamine receptor protein. An inhibitor of tick octopamine receptor protein activity, or function, can be identified using tick octopamine receptor proteins of the present invention. A preferred inhibitor of tick octopamine receptor protein function is a compound capable of substantially interfering with the function of a tick octopamine receptor protein and which does not substantially interfere with the function of host animal octopamine receptor proteins. As used herein, a compound that does not substantially inhibit or interfere with host animal octopamine receptor proteins is one that, when administered to a host animal, the host animal shows no significant adverse effects attributable to the inhibition of octopamine receptor and which, when administered to an animal in an effective manner, is capable of protecting that animal from tick infestation.

One embodiment of the present invention is a method to identify a compound capable of inhibiting tick octopamine receptor protein activity. Such a method includes the steps of (a) contacting (e.g., combining, mixing) an isolated tick octopamine receptor protein of the present invention, with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has tick octopamine receptor protein activity, and (b) determining if the putative inhibitory compound inhibits the activity. Tick octopamine receptor protein activity can be determined in a variety of ways known in the art, including

but not limited to determining the ability of tick octopamine receptor protein to bind to or otherwise interact with a substrate. Such conditions under which a tick octopamine receptor protein has tick octopamine receptor protein activity include conditions in which a tick octopamine receptor protein has a correct three-dimensionally folded structure under physiologic conditions, i.e. physiologic pH, physiologic ionic concentrations, and physiologic temperatures, such as a native protein, a mature protein, a soluble protein, transfected cells or viruses. Accordingly, the correct three-dimensionally folded structure could be used to predict inhibitory compounds.

Putative inhibitory compounds to screen include antibodies (including fragments and mimetopes thereof), putative substrate analogs, and other, preferably small, organic or inorganic molecules. Methods to determine tick octopamine receptor protein activity are known to those skilled in the art, see for example Han et al. 1996, Neuron 16:1127-1135.

A preferred method to identify a compound capable of inhibiting tick octopamine receptor protein activity includes contacting an isolated tick octopamine receptor protein of the present invention with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has tick octopamine receptor protein activity; and determining if the putative inhibitory compound inhibits the activity.

A preferred method to identify a compound capable of inhibiting tick octopamine receptor protein activity includes contacting a recombinant cell comprising an isolated tick octopamine receptor protein of the present invention with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has tick octopamine receptor protein activity; and determining if the putative inhibitory compound inhibits the activity.

Another embodiment of the present invention is an assay kit to identify an inhibitor of a tick octopamine receptor protein of the present invention. This kit comprises an isolated tick octopamine receptor protein of the present invention, and a means for determining inhibition of an activity of tick octopamine receptor protein, where the means enables

detection of inhibition. Detection of inhibition of tick octopamine receptor protein identifies a putative inhibitor to be an inhibitor of a tick octopamine receptor protein. Means for determining inhibition of a tick octopamine receptor protein include, for example, an assay system that detects binding of a putative inhibitor to a tick octopamine receptor molecule, and an assay system that detects interference by a putative inhibitor of the ability of tick octopamine receptor protein to bind octopamine. Means and methods are described herein and are known to those skilled in the art.

5 The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention. The following examples include a
10 number of recombinant DNA and protein chemistry techniques known to those skilled in the art; see, for example, Sambrook et al., *ibid.*

Example 1

This example describes the preparation of tick genomic DNA and a tick head and
15 nerve cord cDNA pool by Rapid Amplification of cDNA Ends (RACE pool).

Genomic DNA was isolated from adult ticks as follows. Four adult *Rhipicephalus*
15 *sanguineus* were crushed in a mortar & pestle using DNAzolTM reagent, available from Life
Technologies, Rockville, MD, and genomic DNA was recovered according to manufacturer's
instructions. Resultant DNA was resuspended in 50 µL T.E. and had an estimated
20 concentration of 50ng/µL.

A tick cDNA RACE pool was constructed as follows. Approximately 10 unfed adult
25 *Rhipicephalus sanguineus* were ground to a homogenized powder by mortar and pestle in
liquid nitrogen. Total RNA was isolated from the resulting homogenized powder using a
modification of the acid-guanidinium-phenol-chloroform method described by Chomczynski
et al., 1987, Anal. Biochem. 162, p. 156-159, which is incorporated herein by reference in its

entirety. The modification of the method is that solution D described by Chomczynski et al. was changed to a solution of 4 M guanidine isothiocyanate, 25 mM Sodium Citrate pH 7.0, 1.5% Sarcosyl, 0.5 M 2-mercaptoethanol. Spectrophotometer and ethidium bromide stained denaturing gel analyses indicated that the yield of total RNA was approximately 43 µg.

5 Approximately 10 µg of total RNA was used as template to construct a RACE pool using a Marathon cDNA Amplification Kit, available from Clontech Laboratories, Inc., Palo Alto, CA, according to the manufacturer's instructions.

Example 2

This example describes the cloning and sequencing of tick octopamine receptor
10 nucleic acid molecules.

PCR primers whose sequence was obtained from Van Poyer et al., Insect Biochemistry and Molecular Biology, 31 (2001) 333-338 were used to amplify an approximately 100 nucleotide product from genomic DNA of adult, unfed ticks prepared as described above. Forward primer 5' GCCATCATYG TGGGCRKSTT CATCKTBTGC
15 TGG 3', designated SEQ ID NO:13, was used in combination with reverse primer 5' GATCATSGGR TTWAYGGCSG AGTTGCAGTA GCC 3', designated SEQ ID NO:14, in a PCR reaction using 2uL of genomic DNA, 2.5 units (U) AmpliTaq polymerase, available from PE Biosystems, Foster City, CA, 0.2 mM dNTP's and 1.0 µM primers, in a total reaction volume of 50 µL. The following amplification conditions were used: (1) one cycle
20 of 95°C for 1 minute, (2) five cycles of 94°C for 10 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, (3) ten cycles of 94°C for 10 seconds, 57°C for 30 seconds, and 72°C for 30 seconds, (4) twenty-five cycles of 94°C for 10 seconds, 54°C for 30 seconds, and 72°C for 45 seconds. The resulting product, referred to as nRsOCR₁₀₂, was excised from an agarose gel

and T/A cloned using the Topo TA cloning kitTM from Invitrogen and sequenced to reveal a 102 nucleotide product, having a coding strand designated SEQ ID NO:1 and a complementary strand designated SEQ ID NO:3.

First and second PCR reactions were performed on the tick cDNA library prepared as described in Example 1 under the following reaction conditions: 2.5 U AdvantageTM polymerase per reaction, available from Clonetech, Palo Alto, CA, 0.2 mM dNTP's, and 0.5 μ M primers, in a total reaction volume of 50 μ L, were used under the following cycling conditions: (1) one cycle of 94°C for 30 seconds, (2) five cycles of 94°C for 5 seconds, 64°C for 4 minutes, (3) five cycles of 94°C for 5 seconds, 66°C for 4 minutes, (4) five cycles of 94°C for 5 seconds, 68°C for 4 minutes, and (5) one cycle of 72°C for three minutes. In the first PCR reaction, a forward primer having the sequence 5' GCTGGCTGCC ATTCTCACC GTG 3', designated SEQ ID NO:15 was used in combination with a primer corresponding to sequence within the adapter flanking the termini of all fragments in the cDNA RACE pool, having the sequence 5' CCATCCTAAT ACGACTCACT ATAGGGC 3', designated SEQ ID NO:16. Five μ L of a 1/250 dilution of tick cDNA RACE pool was used as template. One μ L of the resulting reaction product was used in a second PCR reaction using SEQ ID NO:16 as the reverse primer in combination with a forward primer having the sequence 5' GGTGCGTGCA TTCTGCGAGC ACTG 3', designated SEQ ID NO:17. The resulting PCR product was excised from an agarose gel and T/A cloned using the TOPO T/ATM cloning kit, available from Invitrogen, Carlsbad, CA. The purified product, denoted nRsOCR₄₉₉, was sequenced and shown to contain 499 base pairs, having a coding strand designated SEQ ID NO:4 and a complementary strand designated SEQ ID NO:6. Sequence analysis of SEQ ID NO:4 indicates that nRsOCR₄₉₉ encodes a protein denoted PRsOCR₉₂,

having a sequence represented by SEQ ID NO:5, assuming an open reading frame extending from nucleotide 3 through nucleotide 278 of SEQ ID NO:4. Sequence analysis further demonstrated that SEQ ID NO:5 represents the C-terminus of a tick octopamine receptor.

To isolate the 5' portion of a tick octopamine receptor, first and second PCR reactions were performed on the tick cDNA library prepared as described in Example 1 under the following reaction conditions: 2.5 U AdvantageTM polymerase per reaction, 0.2 mM dNTP's, and 0.5 μ M primers, in a total reaction volume of 50 μ L, were used under the following cycling conditions: (1) one cycle of 95°C for 1 minute, (2) five cycles of 94°C for 10 seconds, 66°C for 30 seconds, 72°C for 1 minute, (3) thirty cycles of 94°C for 10 seconds, 63°C for 20 seconds, 72°C for two minutes.

In the first PCR reaction, a forward primer SEQ ID NO:16 was used in combination with a reverse primer having nucleotide sequence 5' AGAAGACCGA GAACAGCAGG TTGG 3', designated SEQ ID NO:18. Three μ L of a 1/250 dilution of tick cDNA RACE pool was used as template. One μ L of the resulting reaction product was used as the template in a second PCR reaction using SEQ ID NO:16 as the reverse primer in combination with a forward primer having the sequence 5' TGGCACCAAGG TGTGGCCGAA GAGCCACAC 3', designated SEQ ID NO:19. The resulting PCR product was excised from an agarose gel and T/A cloned using a TOPO T/ATM cloning kit. The purified product, denoted nRsOCR₂₈₆, was sequenced and shown to contain 286 base pairs, having a coding strand designated SEQ ID NO:7 and a complementary strand designated SEQ ID NO:9. Sequence analysis of SEQ ID NO:7 indicates that nRsOCR₂₈₆ encodes a protein denoted PRsOCR₉₅, having a sequence represented by SEQ ID NO:8, assuming an open reading frame extending from nucleotide 1 through nucleotide 285 of SEQ ID NO:7.

Sequence analysis further demonstrated that SEQ ID NO:8 represents the N-terminus of a tick octopamine receptor.

Sequence information from SEQ ID NO:3 and SEQ ID NO:6 was used to design primers to amplify one contiguous piece of DNA encoding the entire open reading frame of the nucleic acid molecule encoding a tick octopamine receptor and a PCR reaction was conducted as follows. A forward primer having nucleotide sequence 5' ATGAACGAGA CGTGCCTGTC CCGC 3', designated SEQ ID NO:20 was used in conjunction with a reverse primer having nucleotide sequence, 5' CTAGGGCGAC GCGGCGTTGT CCGG 3', designated SEQ ID NO:21. The following reaction conditions were used: 2.5 U Advantage™ polymerase per reaction, five µL of a 1/250 dilution of tick cDNA RACE pool as template, 0.2 mM dNTP, and 0.5 µM primers, in a total reaction volume of 50 µL. The following cycling conditions were used: (1) one cycle of 94°C for 5 minutes, (2) five cycles of 94°C for 5 seconds, 72°C for 2.5 minutes, (3) 5 cycles of 94°C 5 seconds, 70°C 2.5 minutes, (4) thirty-five cycles of 94°C for 5 seconds, 68°C for 2.5 minutes, and (5) one cycle of 72°C for 7 minutes. The resulting approximately 1500 nucleotide PCR product was excised from an agarose gel, purified using a Qiaquick™ kit, available from Qiagen, Chatsworth, CA, and T/A cloned using a TOPO T/A cloning kit. The purified product, referred to as nRsOCR₁₄₄₃ was sequenced and shown to contain 1443 base pairs, having a coding strand designated SEQ ID NO:10 and a complementary strand designated SEQ ID NO:12. Sequence analysis of SEQ ID NO:10 indicates that nRsOCR₁₄₄₃ encodes a protein denoted PRsOCR₄₈₀, having a sequence represented by SEQ ID NO:11, assuming an open reading frame extending from nucleotide 1 through nucleotide 1440 of SEQ ID NO:10.

Sequence analysis further demonstrated that SEQ ID NO:11 represents an open reading frame encoding a full-length tick octopamine receptor.

Comparison of nucleic acid SEQ ID NO:10 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:10 shared the most similarity, i.e. about 57% with a 5 *Balanus amphitrite* gene for G protein-coupled receptor (GenBank accession number D78587). Comparison of amino acid sequence SEQ ID NO:11 with amino acid sequences reported in GenBank indicates that SEQ ID NO:11 showed the most similarity, i.e. about 10 52%, with an *Anopheles gambiae* str. PEST (genome seq conceptual translation) and a second highest similarity to a *Balanus amphitrite* G-protein coupled receptor (GenBank accession number BAA11424).

While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims:

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:
 - (a) a nucleic acid molecule at least 50 nucleotides in length that hybridizes with a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12, under conditions comprising: (1) hybridizing in a solution comprising 2X SSC in the absence of nucleic acid helix destabilizing compounds, at a temperature of 37°C; and (2) washing in a solution comprising 1X SSC in the absence of helix destabilizing compounds, at a temperature of 10 66.8°C; wherein said at least 50 nucleotide nucleic acid molecule encodes a protein that binds to octopamine; and
 - (b) a nucleic acid molecule fully complementary to the nucleic acid molecule of (a).
2. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.
3. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.
- 20 4. A recombinant molecule comprising a nucleic acid molecule as set forth in Claim 1 operatively linked to a transcription control sequence.
5. A recombinant virus comprising a nucleic acid molecule as set forth in Claim 1.
6. A recombinant cell comprising a nucleic acid molecule as set forth in Claim 1.

P-FC-10

7. A method to produce a protein encoded by an isolated nucleic acid molecule of Claim 1, said method comprising culturing a cell transformed with a nucleic acid molecule encoding said protein.
8. An isolated nucleic acid molecule selected from the group consisting of:
 - 5 (a) a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 AND SEQ ID NO:10, and variants thereof at least 95% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 AND SEQ ID NO:10, wherein said nucleic acid molecule encodes a protein that binds to octopamine;
 - 10 (b) a nucleic acid molecule comprising a fragment of a nucleic acid molecule of (a), wherein said fragment is at least 50 nucleotides in length; and
 - (c) a nucleic acid molecule fully complementary to a nucleic acid molecule of (a) or (b).
9. The nucleic acid molecule of Claim 8, wherein said nucleic acid molecule comprises 15 a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.
10. The nucleic acid molecule of Claim 8, wherein said nucleic acid molecule encodes a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.
- 20 11. A recombinant molecule comprising a nucleic acid molecule as set forth in Claim 8 operatively linked to a transcription control sequence.
12. A recombinant virus comprising a nucleic acid molecule as set forth in Claim 8.
13. A recombinant cell comprising a nucleic acid molecule as set forth in Claim 8.

14. A method to produce a protein encoded by an isolated nucleic acid molecule of Claim 8, said method comprising culturing a cell transformed with a nucleic acid molecule encoding said protein.
15. An isolated protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, and variants thereof that are at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11, wherein said protein variant binds to octopamine.
16. The protein of Claim 15, wherein said protein is encoded by a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 AND SEQ ID NO:10.
17. The protein of Claim 15, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.
18. An isolated antibody that selectively binds to a protein as set forth in Claim 15.
19. A method to detect an inhibitor of tick octopamine receptor activity, said method comprising (a) contacting an isolated tick octopamine receptor protein of Claim 15, with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has tick octopamine receptor protein activity, and (b) determining if said putative inhibitory compound inhibits tick octopamine receptor protein activity.
20. The method of Claim 19, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and SEQ ID NO:11.

ABSTRACT

The present invention relates to tick octopamine receptor nucleic acid molecules; to tick octopamine receptor proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes inhibitory compounds, particularly those that specifically inhibit tick octopamine receptor activity, as well as the use of such compounds to treat animals.

10

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am an official empowered to act on behalf of Heska Corporation of 1613 Prospect Parkway, Fort Collins, Colorado 80525, a small business concern.

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled "TICK OCTOPAMINE RECEPTOR NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF," and identified as Attorney File No. P-FC-10, described in the specification filed herewith.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____

INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT

ORGANIZATION

NAME _____

ADDRESS _____

INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT

ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Dated: November 15, 2002

By: Carol Talkington Verter
Carol Talkington Verter, Ph.D.
Executive Vice President
Intellectual Property and Business Development
Heska Corporation
1613 Prospect Parkway
Fort Collins, Colorado 80525

P-FC-10.ST25.txt
SEQUENCE LISTING

<110> Brandt, Kevin S.

<120> TICK OCTOPAMINE RECEPTOR NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF

<130> P-FC-10

<140> not yet assigned
<141> 2002-11-15

<160> 21

<170> PatentIn version 3.1

<210> 1
<211> 102
<212> DNA
<213> Rhipicephalus sanguineus

<220>
<221> CDS
<222> (1)...(102)
<223>

<400> 1
gcc atc att gtg ggc atc ttc atc gtg tgc tgg att aca gtg cat acc
Ala Ile Ile Val Gly Ile Phe Ile Val Cys Trp Ile Thr Val His Thr
1 5 10 15

48

ttt aga ttc ttt aag caa aca ctt ggc tac tgc aac tcg gcc ata aac
Phe Arg Phe Phe Lys Gln Thr Leu Gly Tyr Cys Asn Ser Ala Ile Asn
20 25 30

96

ccc aga
Pro Arg

102

<210> 2
<211> 34
<212> PRT
<213> Rhipicephalus sanguineus

<400> 2

Ala Ile Ile Val Gly Ile Phe Ile Val Cys Trp Ile Thr Val His Thr
1 5 10 15

Phe Arg Phe Phe Lys Gln Thr Leu Gly Tyr Cys Asn Ser Ala Ile Asn
20 25 30

Pro Arg

P-FC-10.ST25.txt

<210> 3
 <211> 102
 <212> DNA
 <213> Rhipicephalus sanguineus

<400> 3
 tctgggttt atggccgagt tgcagtagcc aagtgttgc ttaaagaatc taaaggtatg 60
 cactgtaatc cagcacacga tgaagatgcc cacaatgatg gc 102

<210> 4
 <211> 499
 <212> DNA
 <213> Rhipicephalus sanguineus

<220>
 <221> CDS
 <222> (3)..(278)
 <223>

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n = unknown

<400> 4
 tg tct tan gag tca tca ccg tgg cat tcg ccc ttg gtg cgt gca ttc 47
 Ser Xaa Glu Ser Ser Pro Trp His Ser Pro Leu Val Arg Ala Phe
 1 5 10 15

tgc gag cac tgc atc ccc aac ctg ctg ttc tcg gtc ttc ttc tgg ctc 95
 Cys Glu His Cys Ile Pro Asn, Leu Leu Phe Ser Val Phe Phe Trp Leu
 20 25 30

gga tac tgc aac tcg gcc atc aac ccg ctc atc tac gtg ctt gtc agc 143
 Gly Tyr Cys Asn Ser Ala Ile Asn Pro Leu Ile Tyr Val Leu Val Ser
 35 40 45

aag gac ttt cgg ctg gcc ttc aag cgc atc ctg tgt cgc tgc cgc ctc 191
 Lys Asp Phe Arg Leu Ala Phe Lys Arg Ile Leu Cys Arg Cys Arg Leu
 50 55 60

aaa gaa gga ggc gtc tcg tca ctc atc aaa cag atc cac atg ctc acc 239
 Lys Glu Gly Val Ser Ser Leu Ile Lys Gln Ile His Met Leu Thr
 65 70 75

gta ctt gac gac gca ccc ccg gac aac gcc gag tcg ccc tagaattctcg 288
 Val Leu Asp Asp Ala Pro Pro Asp Asn Ala Glu Ser Pro
 80 85 90

gtcacaggct tctcctgccc gcgcstatcgc ggcattctca tggggcgcca ctgcttcttt 348
 gcacacctacc cgctcaactgc accgcgtgtc tctgcgttag tgacattgtc ggtgtccatc 408
 tcacggctgt aatgtctcct tcctcaccca cgtgaatcac cactatagcc acagagcaa 468

499

cgtgccagta ccaagagcgc ttctgcccga c

<210> 5
<211> 92
<212> PRT
<213> Rhipicephalus sanguineus

<220>
<221> misc_feature
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Tyr

<400> 5

Ser	Xaa	Glu	Ser	Ser	Pro	Trp	His	Ser	Pro	Leu	Val	Arg	Ala	Phe	Cys
1														15	

Glu	His	Cys	Ile	Pro	Asn	Leu	Leu	Phe	Ser	Val	Phe	Phe	Trp	Leu	Gly
20														30	

Tyr	Cys	Asn	Ser	Ala	Ile	Asn	Pro	Leu	Ile	Tyr	Val	Leu	Val	Ser	Lys
35														45	

Asp	Phe	Arg	Leu	Ala	Phe	Lys	Arg	Ile	Leu	Cys	Arg	Cys	Arg	Leu	Lys
50													60		

Glu	Gly	Gly	Val	Ser	Ser	Leu	Ile	Lys	Gln	Ile	His	Met	Leu	Thr	Val
65														80	

Leu	Asp	Asp	Ala	Pro	Pro	Asp	Asn	Ala	Glu	Ser	Pro				
85															

<210> 6
<211> 499
<212> DNA
<213> Rhipicephalus sanguineus

<220>
<221> misc_feature
<222> (492)..(492)
<223> n = unknown

<400> 6															60
gtgcggcaga	agcgcttgc	gtactggcac	gtttgtcttg	tggctatagt	ggtgattcac										
gtgggtgagg	aaggagacat	tacagccgtg	agatggacac	cgacaatgtc	actacggcag										120
agacacgcgg	tgcagtgagc	gggtgaggtg	caaagaagca	gtggcgcccc	atgagaatgc										180
cgcgatagcg	cgggcaggag	aaggctgtga	ccaggattct	agggcgactc	ggcggttgtcc										240

P-FC-10.ST25.txt

gggggtgcgt cgtcaagtac ggtgagcatg tggatctgtt tgatgagtga cgagacgcct 300
 ccttcattga ggccggcagcg acacaggatg cgcttgaagg ccagccgaaa gtccttgctg 360
 acaagcacgt agatgagcgg gttgatggcc gagttgcagt atccgagcca gaagaagacc 420
 gagaacagca ggttggggat gcagtgcac cagaatgcac gcaccaaggg cgaatgccac 480
 ggtgatgact cntaagaca 499

<210> 7
 <211> 286
 <212> DNA
 <213> Rhipicephalus sanguineus

<220>
 <221> CDS
 <222> (1)...(285)
 <223>

<400> 7
 cgg ccc ggt agc aac atg aac gag acg tgc ctg tcc cgc gtg ccg cca 48
 Arg Pro Gly Ser Asn Met Asn Glu Thr Cys Leu Ser Arg Val Pro Pro
 1 5 10 15
 gag aag ctc cat gag ccg gtc act gtg gcc ctg ttc ttc gta ctg ggc 96
 Glu Lys Leu His Glu Pro Val Thr Val Ala Leu Phe Phe Val Leu Gly
 20 25 30
 tcc atc aat gga ctc gtc atc ttc ggt aac ctg ctg gtc att atc gcc 144
 Ser Ile Asn Gly Leu Val Ile Phe Gly Asn Leu Leu Val Ile Ile Ala
 35 40 45
 gtg ctg gcc tca aca aag ctg cgc acg gtc acc aac tac ttc gtg gtg 192
 Val Leu Ala Ser Thr Lys Leu Arg Thr Val Thr Asn Tyr Phe Val Val
 50 55 60
 tcc ttg gct gtg gcc gac ctc tcg gtt ggg ctc acc gtg ttg cca tac 240
 Ser Leu Ala Val Ala Asp Leu Ser Val Gly Leu Thr Val Leu Pro Tyr
 65 70 75 80
 tca att gtg ttg gag gtg ctc gag gtg tgg ctc ttc ggc caa cct g 286
 Ser Ile Val Leu Glu Val Leu Glu Val Trp Leu Phe Gly Gln Pro
 85 90 95

<210> 8
 <211> 95
 <212> PRT
 <213> Rhipicephalus sanguineus

<400> 8
 Arg Pro Gly Ser Asn Met Asn Glu Thr Cys Leu Ser Arg Val Pro Pro
 1 5 10 15

P-FC-10.ST25.txt

Glu Lys Leu His Glu Pro Val Thr Val Ala Leu Phe Phe Val Leu Gly
 20 25 30

Ser Ile Asn Gly Leu Val Ile Phe Gly Asn Leu Leu Val Ile Ile Ala
 35 40 45

Val Leu Ala Ser Thr Lys Leu Arg Thr Val Thr Asn Tyr Phe Val Val
 50 55 60

Ser Leu Ala Val Ala Asp Leu Ser Val Gly Leu Thr Val Leu Pro Tyr
 65 70 75 80

Ser Ile Val Leu Glu Val Leu Glu Val Trp Leu Phe Gly Gln Pro
 85 90 95

<210> 9

<211> 286

<212> DNA

<213> Rhipicephalus sanguineus

<400> 9
 caggttggcc gaagagccac acctcgagca cctccaacac aattgagtat ggcaacacgg 60
 tgagccaaac cgagaggctcg gccacagcca aggacaccac gaagtagttg gtgaccgtgc 120
 gcagcttgc tgaggccagc acggcgataa tgaccagcag gttaccgaag atgacgagtc 180
 cattgatgga gcccagtacg aagaacaggg ccacagtgac cggctcatgg agttctctg 240
 gcggcacgacg ggacaggcac gtctcggtca tggctacc gggccg 286

<210> 10

<211> 1443

<212> DNA

<213> Rhipicephalus sanguineus

<220>

<221> CDS

<222> (1)..(1440)

<223>

<400> 10
 atg aac gag acg tgc ctg tcc cgc gtg ccg cca gag aag ctc cat gag 48
 Met Asn Glu Thr Cys Leu Ser Arg Val Pro Pro Glu Lys Leu His Glu
 1 5 10 15
 ccg gtc act gtg gcc ctg ttc gta ctg ggc tcc atc aat gga ctc
 Pro Val Thr Val Ala Leu Phe Phe Val Leu Gly Ser Ile Asn Gly Leu 96
 20 25 30
 gtc atc ttc ggt aac ctg ctg gtc att atc gcc gtg ctg gcc tca aca
 Page 5 144

P-FC-10.ST25.txt

Val Ile Phe Gly Asn Leu Leu Val Ile Ile Ala Val Leu Ala Ser Thr	45	
35	40	
aag ctg cgc acg gtc acc aac tac ttc gtg gtg tcc ttg gct gtg gcc	192	
Lys Leu Arg Thr Val Thr Asn Tyr Phe Val Val Ser Leu Ala Val Ala		
50	55	60
gac ctc tcg gtt ggg ctc acc gtg ttg cca tac tca att gtg ttg gag	240	
Asp Leu Ser Val Gly Leu Thr Val Leu Pro Tyr Ser Ile Val Leu Glu		
65	70	75
gtg ctc gag gtg tgg atc ttc ggc cac acc tgg tgc cag ata tgg cta	288	
gtg Val Leu Glu Val Trp Ile Phe Gly His Thr Trp Cys Gln Ile Trp Leu		
85	90	95
gct gtg gac gta tgg ctc tgc aca tca tcc atc ctg aat ctc tgc gcc	336	
Ala Val Asp Val Trp Leu Cys Thr Ser Ser Ile Leu Asn Leu Cys Ala		
100	105	110
atc agc gtg gac cgc tac ttg gcc atc acg cgg ccg gtt cgc tac cgg	384	
Ile Ser Val Asp Arg Tyr Leu Ala Ile Thr Arg Pro Val Arg Tyr Arg		
115	120	125
agc ctc atg tcg tcg cgc gcc aag ttg ctc atc gtg gcg gtg tgg	432	
Ser Leu Met Ser Ser Arg Arg Ala Lys Leu Leu Ile Val Ala Val Trp		
130	135	140
gtg atc gcc ttt gtc atc tgc ttc ccg ccg ctc gtt gga tgg aac gac	480	
Val Ile Ala Phe Val Ile Cys Phe Pro Pro Leu Val Gly Trp Asn Asp		
145	150	155
160		
ggc ggg tct caa aac agc gtg cct tac cac ggg tcg aac gag acc ttg	528	
Gly Gly Ser Gln Asn Ser Val Pro Tyr His Gly Ser Asn Glu Thr Leu		
165	170	175
cac aat tcg agc atc gct gcc gat ggc ccg ttg ccg ctc tgc aag tcc	576	
His Asn Ser Ser Ile Ala Ala Asp Gly Pro Leu Pro Leu Cys Lys Ser		
180	185	190
gca caa tgt gtg ctg ata aac aac aag ggc tac gtc atc tac tcg gct	624	
Ala Gln Cys Val Leu Ile Asn Asn Lys Gly Tyr Val Ile Tyr Ser Ala		
195	200	205
ctg ggc tct ttc tac ata ccg atg ctg ttc atg ctg ttt ttc aac tac	672	
Leu Gly Ser Phe Tyr Ile Pro Met Leu Phe Met Leu Phe Phe Asn Tyr		
210	215	220
cgc ata tac cgc gca gcc atc cag act ggg cgc gcc ctt gaa cga ggt	720	
Arg Ile Tyr Arg Ala Ala Ile Gln Thr Gly Arg Ala Leu Glu Arg Gly		
225	230	235
240		
ttc ata acc aca aag tca gga aag atc aag gga cgc aca acg gac cag	768	
Phe Ile Thr Thr Lys Ser Gly Lys Ile Lys Gly Arg Thr Asp Gln		
245	250	255
agg ctc acg cta cgc gtc cac cgc ggt aac gat tcc gct atg aac gcc	816	
Arg Leu Thr Leu Arg Val His Arg Gly Asn Asp Ser Ala Met Asn Ala		
260	265	270

P-FC-10.ST25.txt
 aag cga ggt agc gag cac ctc ggt gct gag acc tgc atc gat ggc atc 864
 Lys Arg Gly Ser Glu His Leu Gly Ala Glu Thr Cys Ile Asp Gly Ile
 275 280 285
 gtc acc ggt cgt cgc cgg ccc gga ctd aag aag tcg cgc gac gag ccg 912
 Val Thr Gly Arg Arg Pro Gly Leu Lys Ser Arg Asp Glu Pro
 290 295 300
 tca gcc agc gcc cgg tcg tca gcc agc aag acg cgt cag caa agt gac 960
 Ser Ala Ser Ala Arg Ser Ser Ala Ser Lys Thr Arg Gln Gln Ser Asp
 305 310 315 320
 cag cgg acc acg cgc tcg gcg ccc tcg ttc aag tcg aac agg ggc 1008
 Gln Arg Thr Thr Arg Ser Ala Pro Pro Ser Phe Lys Ser Asn Arg Gly
 325 330 335
 agc gcc cgc aac agt gga cgc aac ggc act tcc acg tct agc ggc ggc 1056
 Ser Ala Arg Asn Ser Gly Arg Asn Gly Thr Ser Thr Ser Gly Gly
 340 345 350
 ggc aag ggc tcg cgt tcg agc aaa cgc agt caa cgg tgg cag gcc aag 1104
 Gly Lys Gly Ser Arg Ser Ser Lys Arg Ser Gln Arg Trp Gln Ala Lys
 355 360 365
 cga ttc cgc aca gag gcc aag gcc acc aag acc gtg ggc acc atc gtg 1152
 Arg Phe Arg Thr Glu Ala Lys Ala Thr Lys Thr Val Gly Thr Ile Val
 370 375 380
 ggt ggc ttt ata tgc tgc tgg ctg ccc ttc aca gtg tac ctg gtg 1200
 Gly Gly Phe Ile Cys Cys Trp Leu Pro Phe Phe Thr Val Tyr Leu Val
 385 390 395 400
 cgt gca ttc tgc gag cac tgc atc ccc aac ctg ctg ttc tcg gtc ttc 1248
 Arg Ala Phe Cys Glu His Cys Ile Pro Asn Leu Leu Phe Ser Val Phe
 405 410 415
 ttc tgg ctc gga tac tgc aac tcg gcc atc aac ccg ctc atc tac gtg 1296
 Phe Trp Leu Gly Tyr Cys Asn Ser Ala Ile Asn Pro Leu Ile Tyr Val
 420 425 430
 ctt gtc agc aag gac ttt cgg ctg gcc ttc aag cgc atc ctg tgt cgc 1344
 Leu Val Ser Lys Asp Phe Arg Leu Ala Phe Lys Arg Ile Leu Cys Arg
 435 440 445
 tgc cgc ctc aaa gaa gga ggc gtc tcg tca ctc atc aaa cag atc cac 1392
 Cys Arg Leu Lys Glu Gly Val Ser Ser Leu Ile Lys Gln Ile His
 450 455 460
 atg ctc acc gta ctt gac gac gca ccc ccg gac aac gcc gag tcg ccc 1440
 Met Leu Thr Val Leu Asp Asp Ala Pro Pro Asp Asn Ala Glu Ser Pro
 465 470 475 480
 tag

<210> 11
 <211> 480
 <212> PRT
 <213> Rhipicephalus sanguineus

P-FC-10.ST25.txt

<400> 11

Met Asn Glu Thr Cys Leu Ser Arg Val Pro Pro Glu Lys Leu His Glu
1 5 10 15

Pro Val Thr Val Ala Leu Phe Phe Val Leu Gly Ser Ile Asn Gly Leu
20 25 30

Val Ile Phe Gly Asn Leu Leu Val Ile Ile Ala Val Leu Ala Ser Thr
35 40 45

Lys Leu Arg Thr Val Thr Asn Tyr Phe Val Val Ser Leu Ala Val Ala
50 55 60

Asp Leu Ser Val Gly Leu Thr Val Leu Pro Tyr Ser Ile Val Leu Glu
65 70 75 80

Val Leu Glu Val Trp Ile Phe Gly His Thr Trp Cys Gln Ile Trp Leu
85 90 95

Ala Val Asp Val Trp Leu Cys Thr Ser Ser Ile Leu Asn Leu Cys Ala
100 105 110

Ile Ser Val Asp Arg Tyr Leu Ala Ile Thr Arg Pro Val Arg Tyr Arg
115 120 125

Ser Leu Met Ser Ser Arg Arg Ala Lys Leu Leu Ile Val Ala Val Trp
130 135 140

Val Ile Ala Phe Val Ile Cys Phe Pro Pro Leu Val Gly Trp Asn Asp
145 150 155 160

Gly Gly Ser Gln Asn Ser Val Pro Tyr His Gly Ser Asn Glu Thr Leu
165 170 175

His Asn Ser Ser Ile Ala Ala Asp Gly Pro Leu Pro Leu Cys Lys Ser
180 185 190

Ala Gln Cys Val Leu Ile Asn Asn Lys Gly Tyr Val Ile Tyr Ser Ala
195 200 205

Leu Gly Ser Phe Tyr Ile Pro Met Leu Phe Met Leu Phe Phe Asn Tyr
210 215 220

P-FC-10.ST25.txt

Arg Ile Tyr Arg Ala Ala Ile Gln Thr Gly Arg Ala Leu Glu Arg Gly
 225 230 235 240

Phe Ile Thr Thr Lys Ser Gly Lys Ile Lys Gly Arg Thr Thr Asp Gln
 245 250 255

Arg Leu Thr Leu Arg Val His Arg Gly Asn Asp Ser Ala Met Asn Ala
 260 265 270

Lys Arg Gly Ser Glu His Leu Gly Ala Glu Thr Cys Ile Asp Gly Ile
 275 280 285

Val Thr Gly Arg Arg Pro Gly Leu Lys Lys Ser Arg Asp Glu Pro
 290 295 300

Ser Ala Ser Ala Arg Ser Ser Ala Ser Lys Thr Arg Gln Gln Ser Asp
 305 310 315 320

Gln Arg Thr Thr Arg Ser Ala Pro Pro Ser Phe Lys Ser Asn Arg Gly
 325 330 335

Ser Ala Arg Asn Ser Gly Arg Asn Gly Thr Ser Thr Ser Ser Gly Gly
 340 345 350

Gly Lys Gly Ser Arg Ser Ser Lys Arg Ser Gln Arg Trp Gln Ala Lys
 355 360 365

Arg Phe Arg Thr Glu Ala Lys Ala Thr Lys Thr Val Gly Thr Ile Val
 370 375 380

Gly Gly Phe Ile Cys Cys Trp Leu Pro Phe Phe Thr Val Tyr Leu Val
 385 390 395 400

Arg Ala Phe Cys Glu His Cys Ile Pro Asn Leu Leu Phe Ser Val Phe
 405 410 415

Phe Trp Leu Gly Tyr Cys Asn Ser Ala Ile Asn Pro Leu Ile Tyr Val
 420 425 430

Leu Val Ser Lys Asp Phe Arg Leu Ala Phe Lys Arg Ile Leu Cys Arg
 435 440 445

Cys Arg Leu Lys Glu Gly Gly Val Ser Ser Leu Ile Lys Gln Ile His
 450 455 460

P-FC-10.ST25.txt

Met	Leu	Thr	Val	Leu	Asp	Asp	Ala	Pro	Pro	Asp	Asn	Ala	Glu	Ser	Pro
					470					475					480
465															

<210>	12														
<211>	1443														
<212>	DNA														
<213>	Rhipicephalus sanguineus														
<400>	12														60
ctaggcgac	tcggcggtgt	ccgggggtgc	gtcgtcaagt	acggtgagca	tgtggatctg										
tttcatatgt	gacgagacgc	ctccttcttt	gaggcggcag	cgacacagga	tgcgtttgaa										120
ggccagccga	aagtccctgc	tgacaagcac	gttagatgagc	gggttgatgg	ccgagttgca										180
gtatccgagc	cagaagaaga	ccgagaacag	caggttgggg	atgcagtgtct	cgcagaatgc										240
acgcaccagg	tacactgtga	agaagggcag	ccagcagcat	ataaaagccac	ccacgatggt										300
ccccacggtc	ttgggtggct	tggcctctgt	gcggaatcgc	ttggcctgccc	accgttgact										360
gcgtttgttc	gaacgcgagc	ccttgcgcgc	gccgctagac	gtggaagtgc	cgttgcgtcc										420
actgttgcgg	gchgctgcccc	tgttcgactt	gaacgagggc	ggcgccgagc	gcgtggtccg										480
ctggtcactt	tgctgacgac	tcttgctggc	tgacgaccgg	gcgctggctg	acggctcgta										540
gcgcgacttc	ttgagtccgg	gccggcgacg	accggtgacg	atgcacatcg	tgcaggtctc										600
agcaccggagg	tgctcgctac	ctcgcttggc	gttcatacg	aatcgttac	cgcgggtggac										660
gcgttagcgtg	agcctctgggt	ccgttgcgcg	tcccttgatc	tttcctgact	ttgtggttat										720
gaaacctcgt	tcaagggcgc	gcccagtctg	gatggctgcg	cggtatatgc	ggtagttgaa										780
aaacagcatg	aacagcatcg	gtatgtagaa	agagccaga	gccgagtaga	tgacgtagcc										840
cttgggtttt	atcagcacac	attgtgcgga	cttgcagagc	ggcaacgggc	catcgccagc										900
gatgctcgaa	tttgcaagg	tctcgttcga	cccggtgtaa	ggcacgctgt	tttgagaccc										960
gccgtcggtc	catccaacga	gcggcgaaa	gcagatgaca	aaggcgatca	cccacaccgc										1020
cacgatgagc	aacttggcgc	ggcgacgacg	catgaggctc	cggtagcgaa	ccggccgcgt										1080
gatggccaag	tagcggtcca	cgctgtatggc	gcagagattc	aggatggatg	atgtgcagag										1140
ccatacggtcc	acagctagcc	atatctggca	ccaggtgtgg	ccgaagatcc	acacctcgag										1200
cacctccaac	acaatttgagt	atggcaaacac	ggtgagccca	accgagaggt	cggccacagc										1260
caaggacacc	acgaagttagt	tggtgaccgt	gcgcagcttt	gttgaggcca	gcacggcgat										1320
aatgaccagc	aggtaaccga	agatgacgag	tccattgtatg	gagccagta	cgaagaacag										1380
ggccacagt	accggctcat	ggagcttc	tggcgacacg	cgggacagggc	acgtctcgat										1440

P-FC-10.ST25.txt

1443

cat

<210> 13
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 13
gccccatcaty g tgggc rkstt catcktb tgc tgg

33

<210> 14
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 14
gatcatsggr ttwayggcsg agttgcagta gcc

33

<210> 15
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 15
gctggctgcc attcttcacc gtg

23

<210> 16
<211> 27
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 16
ccatccta at acgactcact ataggc

27

<210> 17
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

P-FC-10.ST25.txt

<400> 17
ggtcgtgca ttctgcgagc actg

24

<210> 18
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 18
agaagaccga gaacagcagg ttgg

24

<210> 19
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 19
tggcaccagg tgtggccgaa gagccacac

29

<210> 20
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 20
atgaacgaga cgtgcctgtc ccgc

24

<210> 21
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic Primer

<400> 21
ctagggcgac gcggcggtgt ccgg

24